famotidine has been researched along with Curling Ulcer in 169 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Curling Ulcer: Acute stress DUODENAL ULCER, usually observed in patients with extensive third-degree burns.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed two 24-week double-blind trials (REDUCE-1 and -2 (Registration Endoscopic Studies to Determine Ulcer Formation of HZT-501 Compared with Ibuprofen: Efficacy and Safety Studies)) to assess whether double-dose famotidine given in a single-tablet combination with ibuprofen (HZT-501) significantly reduces gastric and duodenal ulcers as compared with ibuprofen." | 9.16 | Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. ( Bello, AE; Grahn, AY; Kivitz, AJ; Laine, L; Schiff, MH; Taha, AS, 2012) |
| "To compare the effect and security of Jinghua Weikang Capsule (JWC) and famotidine in treating duodenal ulcer." | 9.12 | [Comparative study on Jinghua Weikang Capsule and famotidine in treating duodenal ulcer]. ( Chen, JX; Chen, JY; Ji, F, 2006) |
| "Fifty-three consecutive patients with active duodenal ulcer (DU) were randomly included in a double-blind, double-dummy study to test the healing and relapsing rate of two treatment regimens: famotidine 40 mg nocte for 4-8 weeks, followed by 20 mg for 12 months after healing of the ulcer and colloidal bismuth (CBS) (240 mg bid) for 4-8 weeks, followed by placebo maintenance treatment." | 9.08 | Colloid bismuth versus famotidine in the treatment and prevention of duodenal ulcer relapse: results of a double-blind, double dummy randomized study. ( Colombo, E; Fanti, L; Guslandi, M; Masci, E; Testoni, PA; Tittobello, A, 1995) |
| "To evaluate the effect of intravenous famotidine at a conventional dose of 40 mg/day on 24-h intragastric pH in patients with a bleeding duodenal ulcer, and to determine the dose required to maintain gastric pH > 6 by use of a Gastrojet (MIC, Switzerland) device (a pH meter-controlled programmable pump)." | 9.08 | Maintenance of gastric pH above 6 with intravenous famotidine in patients with a bleeding duodenal ulcer. ( Delchier, JC; el Amine, I; Elouaer-Blanc, L; Lamarque, D; Roudot-Thoraval, F; Stanescu, L, 1995) |
| "A trial was carried out to compare the efficacy and safety of ranitidine 300 mg die, famotidine 40 mg die and omeprazole 20 mg die in short-term treatment of bleeding duodenal ulcer in 3 groups of 15 patients." | 9.08 | [Comparison between ranitidine, famotidine, and omeprazole in the treatment of bleeding duodenal ulcer]. ( Maculotti, L; Pradella, P, 1995) |
| "We studied the efficacy of two doses of famotidine (20 mg and 40 mg, each given orally twice daily), as compared with placebo, in preventing peptic ulcers in 285 patients without peptic ulcers who were receiving long-term NSAID therapy for rheumatoid arthritis (82 percent) or osteoarthritis (18 percent)." | 9.08 | Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. ( Cottrell, J; Hawkey, CJ; Hudson, N; Mann, SG; Russell, RI; Simon, TJ; Sturrock, RD; Swannell, AJ; Taha, AS; Trye, PN, 1996) |
| " Our purpose was to evaluate the occurrence of mycotic infection in patients with duodenal ulcer on anti-ulcer therapy and to compare the effects of cimetidine, famotidine, and omeprazole." | 9.08 | Candida overgrowth after treatment of duodenal ulcer. A comparison of cimetidine, famotidine, and omeprazole. ( Chakrabarti, A; Goenka, MK; Gupta, O; Kochhar, R; Kumar, A; Mehta, SK; Talwar, P, 1996) |
| "A multicentric double-blind trial comparing 600 mg/d of Zinc Acexamate (ACZ) and 40 mg/d of Famotidine (FMT) in the short term treatment of acute duodenal ulcer included 199 patients, diagnosed by endoscopy." | 9.08 | [A multicenter clinical trial. Zinc acexamate versus famotidine in the treatment of acute duodenal ulcer. Study Group of Zinc acexamate (new UP doses)]. ( Arenas, JI; Belda, O; de la Santa, Jw; Diago, A; Domínguez, A; Fernández, C; García-Plaza, A; Martín, L; Pallarés, A; Rodrigo, L, 1996) |
| "One hundred four patients with rheumatoid or osteoarthritis who had gastroduodenal ulceration received famotidine, 40 mg twice daily." | 9.08 | Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. ( Cottrell, J; Hawkey, CJ; Hudson, N; Mann, SG; Russell, RI; Sturrock, RD; Swanell, AJ; Taha, AS; Trye, P, 1997) |
| "1) To validate risk factors for delayed healing of duodenal ulcers identified previously in a pilot study, and 2) To evaluate whether famotidine improves the rate of duodenal ulcer healing and pain relief, compared with ranitidine." | 9.07 | Risk factors for delayed healing of duodenal ulcers treated with famotidine and ranitidine. ( Maislin, G; Reynolds, JC; Schoen, RE; Zangari, GG, 1994) |
| "To verify whether a prolonged (therapeutic) treatment with ranitidine or famotidine may affect blood alcohol concentrations (BAC) in patients with duodenal ulcer (DU)." | 9.07 | Prolonged bedtime treatment with H2-receptor antagonists (ranitidine and famotidine) does not affect blood alcohol levels after ethanol ingestion in male patients with duodenal ulcer. ( Bertol, E; Casini, A; Mari, F; Pizzigallo, AM; Surrenti, C, 1994) |
| "Sixty patients with symptomatic duodenal ulcer were randomized to receive either omeprazole (20 mg each morning) or famotidine (40 mg at night time) for 2-4 weeks in a double-blind parallel group clinical trial." | 9.07 | Omeprazole versus famotidine in the healing and relapse of duodenal ulcer. ( Dasarathy, S; Misra, SC; Sharma, MP, 1993) |
| "The efficacy and safety of omeprazole, in 241 patients with active recurrent duodenal ulcer from 21 Italian centres, was studied in a multicentre double-blind randomized trial comparing 20 mg omeprazole o." | 9.07 | Omeprazole versus famotidine in the short-term treatment of duodenal ulcer disease. ( Annibale, B; Cassetta, MR; Delle Fave, G; Franceschi, M; Quatrini, M; Torsoli, A, 1992) |
| "In a double blind, multicenter, parallel group clinical trial in patients with symptomatic duodenal ulcers, 129 patients were randomized to receive either omeprazole 20 mg once daily (n = 65) or famotidine 40 mg once daily (n = 64) for 2 weeks, and if the ulcers were not healed, for a total of 4 weeks." | 9.07 | Comparative study of omeprazole and famotidine in the treatment of duodenal ulcer. ( Babu, S; Chaubal, C; Kumar, TR; Naidu, MU; Prasad, R; Reddy, DN; Shobha, JC; Subhash, S, 1992) |
| " In this 2:1 randomized, double-blind, multicentre trial lansoprazole 30 mg am was compared to 40 mg famotidine nocte in 264 out-patients suffering from uncomplicated duodenal ulcer." | 9.07 | Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration. ( Grymbowski, T; Hennig, U; Hotz, J; Kleinert, R; Schwarz, JA, 1992) |
| "A randomized controlled study comparing once-a-day morning and once-a-day bedtime administration of 40 mg famotidine in treating duodenal ulcers was carried out in 99 Japanese patients." | 9.07 | A comparative study of once-a-day morning and once-a-day bedtime administration of 40 mg famotidine in treating duodenal ulcers. ( Arita, M; Hoshiko, K; Iida, M; Maeda, K; Okada, M; Okada, Y; Sakamoto, K; Sakurai, T; Yao, T, 1992) |
| "5 mg twice daily), amantadine (100 mg nocte), or with the H2 blockers cimetidine (800 mg nocte), and famotidine (40 mg nocte) in 124 patients with endoscopically proven duodenal ulcer (DU)." | 9.07 | Dopamine agonists prevent duodenal ulcer relapse. A comparative study with famotidine and cimetidine. ( Duvnjak, M; Jagic, V; Mise, S; Petek, M; Rotkvic, I; Rucman, R; Seiwerth, S; Sikiric, P; Suchanek, E; Zjacic-Rotkvic, V, 1991) |
| "Famotidine, a new H2 antagonist in a dose of 40 mg qhs was tried in a clinical trial for the treatment of duodenal ulcer in 25 patients and compared with other H2 antagonists." | 9.06 | Treatment of acute duodenal ulcers with famotidine and its comparison with other H2 blockers. ( Akhtar, MA; Khan, MA; Rashid, P, 1990) |
| "The efficacy and safety of famotidine and ranitidine in the treatment of active duodenal ulcer were compared in a multicentre, randomized, double-blind study." | 9.06 | A multicentre, randomized, double-blind study comparing nocte famotidine or ranitidine for the treatment of active duodenal ulceration. ( Alcalá Santaella, R; Alvárez, E; Castellanos, P; Guardia, J; Guarner, L; Ortiz, J; Pajares, J; Pesquera, R; Piqué, J; Pita, L, 1989) |
| "Six asymptomatic, non-smoking men with endoscopically proven duodenal ulcer disease received single nocturnal doses of placebo, 40 mg famotidine and 300 mg ranitidine each for 1 week prior to serial measurement of pH, peptic activity and serum gastrin concentrations over 24 h and of acid output." | 9.06 | A single night-time dose of famotidine is equivalent to ranitidine in decreasing 24-hour gastric acidity in asymptomatic duodenal ulcer subjects. ( Kirdeikis, J; Marriage, B; Pinchbeck, BR; Prat, A; Thomson, AB; Zuk, L, 1989) |
| "Famotidine (40 mg) and 800 mg cimetidine as single night-time doses were compared in a randomized, double-blind, multicentre study of acute treatment for duodenal ulceration." | 9.06 | Single night-time doses of 40 mg famotidine or 800 mg cimetidine in the treatment of duodenal ulcer. ( Booth, SN; Cochran, KM; Cottrell, J; Crowe, J; Dickinson, RJ; Kennedy, NP; Lee, FI; Mann, SG, 1989) |
| "The efficacy and safety of famotidine and ranitidine in the treatment of active duodenal ulcer were compared in a multicenter, randomized double-blind study." | 9.06 | A multicenter, randomized, double-blind study comparing once-daily bedtime administration of famotidine and ranitidine in the short-term treatment of active duodenal ulcer. ( Alcalá Santaella, R; Alvárez, E; Castellanos, P; Guardia, J; Guarner, L; Ortiz, J; Pajares, J; Pesquera, R; Pique, J; Pita, L, 1989) |
| "The efficacy and safety of famotidine and ranitidine in the treatment of active duodenal ulcer were compared in a multicenter, randomized double-blind study." | 9.06 | A multicenter, randomized, double-blind study comparing a daily bedtime administration of famotidine and ranitidine in short-term treatment of active duodenal ulcer. ( Alcalá-Santaella, R; Alvárez, E; Castellanos, P; Guardia, J; Guarner, L; Ortiz, J; Pajares, J; Pesquera, R; Piqué, J; Pita, L, 1989) |
| "This multicentric, double-blind and prospective study, which involved 41 French Gastroenterology Units, was designed to evaluate the efficacy and safety of famotidine, 40 mg at bedtime, compared to single dose ranitidine, 300 mg, in promoting the healing of duodenal ulcer." | 9.06 | [Comparative efficacy of famotidine and ranitidine in the treatment of acute-phase duodenal ulcer. A French comparative therapeutic trial]. ( Delvaux, M; Hagège, CG; Ribet, A, 1989) |
| "In a double-blind multicenter trial, 100 patients with active duodenal ulcer were treated with a single nocturnal dose of famotidine 40 mg or ranitidine 300 mg." | 9.06 | Treatment of active duodenal ulcers with famotidine. A double-blind comparison with ranitidine. ( Gugler, R; Rohner, HG, 1986) |
| "Famotidine, a new long-acting histamine (H2)-receptor antagonist, has recently been shown to be more effective than placebo in healing active duodenal ulcer." | 9.06 | A multicenter, randomized, double-blind study comparing famotidine with ranitidine in the treatment of active duodenal ulcer disease. ( McCullough, AJ, 1986) |
| "One hundred and thirty-two patients with endoscopically confirmed duodenal ulcers were entered into a 4-6-week double-blind trial of famotidine (Fm) and ranitidine (Rn)." | 9.06 | Comparison of famotidine 40 mg with ranitidine 300 mg at night in short-term duodenal ulcer healing. A South African multicentre study. ( Marks, IN; Wright, JP, 1987) |
| "A multicenter, double-blind, randomized, controlled study was conducted in 234 duodenal ulcer patients to compare the efficacy and safety of the H2-receptor antagonists famotidine and ranitidine in the treatment of duodenal ulcer." | 9.06 | Comparison of once-daily bedtime administration of famotidine and ranitidine in the short-term treatment of duodenal ulcer. A multicenter, double-blind, controlled study. ( Boero, A; Camarri, E; Crespi, M; De Pretis, G; Dobrilla, G; Fontana, G; Ideo, G; Manenti, F; Marenco, G; Piazzi, L, 1987) |
| " The effects have been compared of ranitidine and famotidine on PGE2 content in duodenal ulcer patients." | 9.06 | Action of famotidine and ranitidine on prostaglandin E2 (PGE2) content of fundic and duodenal mucosa in duodenal ulcer patients. ( Carlei, F; D'Alessandro, MD; Lezoche, E; Lomanto, D; Mariani, P; Martelli, A; Nardovino, M; Speranza, V; Vagni, V, 1987) |
| "The efficacy of famotidine, a potent new long-acting H2 receptor antagonist, was compared with cimetidine in 78 patients with endoscopically proven acute duodenal ulcers." | 9.06 | Famotidine versus cimetidine in the treatment of acute duodenal ulcer. Double-blind, randomized clinical trial comparing nocturnal administration of 40 mg famotidine to 800 mg cimetidine. ( Fölsch, UR; Hartmann, H, 1988) |
| "Famotidine was compared to ranitidine in a short-term study on the treatment of duodenal ulcer." | 9.06 | Famotidine in the short and long-term treatment of duodenal ulcer. ( Bettarello, A; Coelho, LG; de Paula Castro, L; Dias Avelar, C; Eisig, JN; Massuda, HK; Villalobos, JJ; Zaterka, S, 1988) |
| "An integrated analysis of the fifteen published prospective multicenter studies that have examined the safety and efficacy of famotidine for the short-term (13) and maintenance (2) therapy of duodenal ulcer included over 2,600 patients." | 9.06 | Famotidine in the management of duodenal ulcer: an analysis of multicenter findings worldwide. ( Reynolds, JC, 1988) |
| "Three double blind crossover studies were carried out to assess the ability of primed infusions of famotidine to raise intragastric pH over 24 hours in 12 duodenal ulcer patients." | 9.06 | Continuous intravenous infusions of famotidine maintain high intragastric pH in duodenal ulcer. ( Kaufman, D; Kempf, M; Merki, HS; Neumann, J; Röhmel, J; Walt, RP; Witzel, L, 1988) |
| "In 11 duodenal ulcer patients, the antisecretory effects of bedtime famotidine 40 mg were compared to those obtained with ranitidine 300 mg and placebo by means of continuous 24-hour intragastric pH monitoring." | 9.06 | Continuous 24-hour intragastric pH monitoring in the evaluation of the effect of a nightly dose of famotidine, ranitidine and placebo on gastric acidity of patients with duodenal ulcer. ( Celle, G; Di Timoteo, E; Magnolia, MR; Mela, GS; Savarino, V; Scalabrini, P, 1987) |
| "185 patients with endoscopically proven duodenal ulcers were randomly allocated to treatment with either famotidine 40 mg nocte, 20 mg bid, 40 mg bid or ranitidine 150 mg bid for 2-8 weeks in a prospective double-blind study." | 9.05 | [Famotidine versus ranitidine in the acute treatment of duodenal ulcer. A multicenter comparative study in Germany]. ( Dammann, HG; Jakob, G; Miederer, SE; Müller, P; Ottenjann, R; Paul, F; Scholten, T; Schütz, E; Seifert, E; Simon, B, 1985) |
| "One-hundred and eight-three patients with endoscopically proven duodenal ulcers, enrolled in this prospective, double-blind study, were randomly allocated to receive famotidine 40 mg once at night, 20 mg twice daily, 40 mg twice daily, or ranitidine 150 mg twice daily for 2-8 weeks." | 9.05 | Famotidine versus ranitidine for the short-term treatment of duodenal ulcer. ( Dammann, HG; Jakob, G; Miederer, SE; Müller, P; Ottenjann, R; Paul, F; Scholten, T; Schütz, E; Seifert, E; Simon, B, 1985) |
| "The new H2 receptor antagonist, famotidine, has been tested in open and double-blind studies in over 2,000 acute duodenal or gastric ulcer patients as well as in the maintenance of chronic duodenal ulcer patients." | 9.05 | Famotidine in the treatment of gastric and duodenal ulceration: overview of clinical experience. ( Bianchi Porro, G, 1985) |
| "The aim of this study was to gain experience concerning efficacy and safety of famotidine, the new H2-receptor antagonist, for the maintenance of duodenal ulcer disease." | 9.05 | [Famotidine versus placebo in prevention of the recurrence of duodenal ulcer disease. A multicenter study in Germany, Austria and Italy]. ( Baglioni, A; Barbara, L; Bianchi-Porro, G; Blasi, A; Canelli, B; Cheli, R; Dal Monte, R; Dammann, HG; Francavilla, A; Hentschel, E, 1985) |
| "Although anti-inflammatory doses of ibuprofen are very effective in treating the signs and symptoms of osteoarthritis (OA), they come with an increased risk for gastrointestinal damage which can limit their use and decrease patient adherence to therapy." | 8.90 | Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials. ( Bello, AE; Grahn, AY; Holt, RJ; Kent, JD; Rice, P, 2014) |
| "The aim was to compare the clinical efficacy of lansoprazole with the efficacies of ranitidine and famotidine in order to rank this drug in the hierarchy of duodenal ulcer treatments." | 8.79 | Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. ( Agostini, H; Lemaire, M; Poynard, T, 1995) |
| "To study the effects of growth factors on experimental duodenal ulcer healing in indomethacin-treated rats." | 7.72 | Effect of exogenous administration of transforming growth factor-beta and famotidine on the healing of duodenal ulcer under the impact of indomethacin. ( Arceiz, E; Lanas, A; Ortego, J; Pérez-Aisa, A; Sainz, R; Sopeña, F, 2003) |
| "Duodenal ulcer was induced in male Wistar rats with acetic acid." | 7.71 | [Effect of exogenous administration of platelet-derived growth factor and epidermal growth factor on duodenal ulcer healing in rats treated with indomethacin]. ( Arceiz Gonzalo, E; Lanas Arbeloa, A; Ortego Díez De Retana, J; Pérez Aisa, A; Sainz Samitier, R; Sopeña Biarge, F, 2002) |
| "The gastrojet, a closed loop pH feedback infusion pump capable of maintaining intragastric pH at a target value by infusing H2 blockers at variable rates, was used to assess factors influencing the quantity of famotidine required to maintain intragastric pH above 4 for 24 hours in 34 fed patients with duodenal ulcers." | 7.69 | Maintenance of intragastric pH > 4 with famotidine in duodenal ulcer patients: factors influencing drug requirements. ( Deharvengt, MC; Delchier, JC; Elouaer Blanc, L; Roudot-Thoraval, F; Stanescu, L, 1994) |
| "The combination of sucralfate (SUC) and famotidine (FAM) at subtherapeutic dose on cysteamine-induced duodenal ulcers (3 x 250 mg/kg) in female rats was studied." | 7.69 | The effect of the combination therapy with sucralfate and famotidine on experimentally induced duodenal ulcers in rats. ( Zupancic, P, 1996) |
| "The studies of microsomal liver enzyme activity by means of a respiratory test with 14C-aminopyrine (ABT) were carried out in 20 patients with duodenal ulcer treated for eight weeks with famotidine." | 7.68 | [Evaluation of microsomal enzyme function in the liver in patients with duodenal ulcer treated with famotidine]. ( Grzeszczak, W; Piotrowska, E; Piotrowski, J, 1993) |
| "The liver microsomal enzymes activity was measured by aminopyrine breath test in 20 subjects with duodenal ulcer disease treated with famotidine for 8 weeks." | 7.68 | [Assessment of microsomal enzyme function in liver of patients with duodenal ulcer treated with famotidine]. ( Grzeszczak, W; Piotrowska, E; Piotrowski, J, 1993) |
| "In this open trial, 25 patients with identified duodenal ulcers were given long-term therapy of a single evening dose of 20 mg famotidine." | 7.68 | [Prevention of the recurrence of duodenal ulcer with famotidine. Report of experiences with long-term therapy in an open clinical study]. ( Judmaier, G, 1992) |
| "Fifty three patients with duodenal ulcer were treated with 40 mg of famotidine at bed time." | 7.67 | A single nocte dose of famotidine in the treatment of duodenal ulcer. ( Ahmad, W; Qureshi, H; Zuberi, SJ, 1989) |
| "The aim of this study was to evaluate the clinical efficacy of short and long-term treatment with famotidine 40 mg/daily at bed time in duodenal ulcer disease." | 7.67 | [Famotidine in the short and long term treatment of duodenal ulcer: clinical and physiopathologic study]. ( Dal Santo, L; Di Mario, F; Gottardello, L; Grassi, SA; Naccarato, R; Pasqualetti, P; Tessaro, P; Vianello, F; Vio, A, 1989) |
| "The H2-receptor antagonists mifentidine, famotidine, cimetidine and ranitidine were examined for their ability to prevent the duodenal ulcer caused by mepirizole (250 mg/kg p." | 7.67 | Effect of mifentidine on mepirizole-induced duodenal ulcer in the rat. ( Brambilla, A; De Paoli, AM; Ghiorzi, A; Giachetti, A, 1987) |
| "Healing processes of duodenal ulcers induced by mepirizole and effects of several drugs on the ulcer healing were studied in rats." | 7.66 | Effects of antiulcer agents on healing of mepirizole-induced duodenal ulcers in rats. ( Ishihara, Y; Okabe, S, 1983) |
| "for the prevention of duodenal ulcer recurrence." | 6.67 | A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse. ( Barbara, L; Bianchi Porro, G; Blasi, A; Bovero, E; Capurso, L; Cheli, R; Corinaldesi, R; Koch, M; Lazzaroni, M; Mangiameli, A, 1991) |
| "Famotidine appears to be an effective and safe once-a-day therapy for the treatment of acute duodenal ulcer disease." | 6.66 | A multicenter, double-blind, randomized, placebo-controlled comparison of nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer disease. ( Berman, R; Gitlin, N; Mantell, G; McCullough, AJ; Smith, JL, 1987) |
| " In view of possible increased patient compliance with a simplified dosage regimen, famotidine 40 mg h." | 6.66 | Review of an extensive worldwide study of a new H2-receptor antagonist, famotidine, as compared to ranitidine in the treatment of acute duodenal ulcer. ( Bianchi Porro, G; Cook, T; Dicenta, C; Humphries, TJ, 1987) |
| "Ibuprofen/famotidine was generally well tolerated, with a tolerability profile consistent with those established for the individual agents." | 6.49 | Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy. ( Deeks, ED, 2013) |
| " Recurrent upper GI bleeding occurred in one patient receiving lansoprazole (duodenal ulcer) and three receiving famotidine (two gastric ulcers and one duodenal ulcer)." | 5.34 | Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial. ( Chan, FKL; Ching, JYL; Chiu, PWY; Lau, JYW; Lau, LHS; Ling, RHY; Tse, YK; Wong, GLH; Wong, VWS, 2020) |
| "Operative management also reduces recurrence rates, which, however, are commoner in patients coming to surgery nowadays." | 5.28 | High doses of ranitidine in maintenance therapy of duodenal ulcer patients. ( Lee, FI, 1990) |
| " The therapy was prolonged for two years with the same dosage at the beginning and later with half doses without any relapse and secondary effects." | 5.28 | [Duodenal ulcer, study of gastric secretion and rational treatment with famotidine in different doses]. ( Idotta, G; Morucci, P; Santoro, E; Scutari, F, 1989) |
| "We performed two 24-week double-blind trials (REDUCE-1 and -2 (Registration Endoscopic Studies to Determine Ulcer Formation of HZT-501 Compared with Ibuprofen: Efficacy and Safety Studies)) to assess whether double-dose famotidine given in a single-tablet combination with ibuprofen (HZT-501) significantly reduces gastric and duodenal ulcers as compared with ibuprofen." | 5.16 | Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. ( Bello, AE; Grahn, AY; Kivitz, AJ; Laine, L; Schiff, MH; Taha, AS, 2012) |
| "To compare the effect and security of Jinghua Weikang Capsule (JWC) and famotidine in treating duodenal ulcer." | 5.12 | [Comparative study on Jinghua Weikang Capsule and famotidine in treating duodenal ulcer]. ( Chen, JX; Chen, JY; Ji, F, 2006) |
| "Fifty-three consecutive patients with active duodenal ulcer (DU) were randomly included in a double-blind, double-dummy study to test the healing and relapsing rate of two treatment regimens: famotidine 40 mg nocte for 4-8 weeks, followed by 20 mg for 12 months after healing of the ulcer and colloidal bismuth (CBS) (240 mg bid) for 4-8 weeks, followed by placebo maintenance treatment." | 5.08 | Colloid bismuth versus famotidine in the treatment and prevention of duodenal ulcer relapse: results of a double-blind, double dummy randomized study. ( Colombo, E; Fanti, L; Guslandi, M; Masci, E; Testoni, PA; Tittobello, A, 1995) |
| "To evaluate the effect of intravenous famotidine at a conventional dose of 40 mg/day on 24-h intragastric pH in patients with a bleeding duodenal ulcer, and to determine the dose required to maintain gastric pH > 6 by use of a Gastrojet (MIC, Switzerland) device (a pH meter-controlled programmable pump)." | 5.08 | Maintenance of gastric pH above 6 with intravenous famotidine in patients with a bleeding duodenal ulcer. ( Delchier, JC; el Amine, I; Elouaer-Blanc, L; Lamarque, D; Roudot-Thoraval, F; Stanescu, L, 1995) |
| "A trial was carried out to compare the efficacy and safety of ranitidine 300 mg die, famotidine 40 mg die and omeprazole 20 mg die in short-term treatment of bleeding duodenal ulcer in 3 groups of 15 patients." | 5.08 | [Comparison between ranitidine, famotidine, and omeprazole in the treatment of bleeding duodenal ulcer]. ( Maculotti, L; Pradella, P, 1995) |
| "We studied the efficacy of two doses of famotidine (20 mg and 40 mg, each given orally twice daily), as compared with placebo, in preventing peptic ulcers in 285 patients without peptic ulcers who were receiving long-term NSAID therapy for rheumatoid arthritis (82 percent) or osteoarthritis (18 percent)." | 5.08 | Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. ( Cottrell, J; Hawkey, CJ; Hudson, N; Mann, SG; Russell, RI; Simon, TJ; Sturrock, RD; Swannell, AJ; Taha, AS; Trye, PN, 1996) |
| " Our purpose was to evaluate the occurrence of mycotic infection in patients with duodenal ulcer on anti-ulcer therapy and to compare the effects of cimetidine, famotidine, and omeprazole." | 5.08 | Candida overgrowth after treatment of duodenal ulcer. A comparison of cimetidine, famotidine, and omeprazole. ( Chakrabarti, A; Goenka, MK; Gupta, O; Kochhar, R; Kumar, A; Mehta, SK; Talwar, P, 1996) |
| "A multicentric double-blind trial comparing 600 mg/d of Zinc Acexamate (ACZ) and 40 mg/d of Famotidine (FMT) in the short term treatment of acute duodenal ulcer included 199 patients, diagnosed by endoscopy." | 5.08 | [A multicenter clinical trial. Zinc acexamate versus famotidine in the treatment of acute duodenal ulcer. Study Group of Zinc acexamate (new UP doses)]. ( Arenas, JI; Belda, O; de la Santa, Jw; Diago, A; Domínguez, A; Fernández, C; García-Plaza, A; Martín, L; Pallarés, A; Rodrigo, L, 1996) |
| "One hundred four patients with rheumatoid or osteoarthritis who had gastroduodenal ulceration received famotidine, 40 mg twice daily." | 5.08 | Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. ( Cottrell, J; Hawkey, CJ; Hudson, N; Mann, SG; Russell, RI; Sturrock, RD; Swanell, AJ; Taha, AS; Trye, P, 1997) |
| "1) To validate risk factors for delayed healing of duodenal ulcers identified previously in a pilot study, and 2) To evaluate whether famotidine improves the rate of duodenal ulcer healing and pain relief, compared with ranitidine." | 5.07 | Risk factors for delayed healing of duodenal ulcers treated with famotidine and ranitidine. ( Maislin, G; Reynolds, JC; Schoen, RE; Zangari, GG, 1994) |
| "To verify whether a prolonged (therapeutic) treatment with ranitidine or famotidine may affect blood alcohol concentrations (BAC) in patients with duodenal ulcer (DU)." | 5.07 | Prolonged bedtime treatment with H2-receptor antagonists (ranitidine and famotidine) does not affect blood alcohol levels after ethanol ingestion in male patients with duodenal ulcer. ( Bertol, E; Casini, A; Mari, F; Pizzigallo, AM; Surrenti, C, 1994) |
| "Sixty patients with symptomatic duodenal ulcer were randomized to receive either omeprazole (20 mg each morning) or famotidine (40 mg at night time) for 2-4 weeks in a double-blind parallel group clinical trial." | 5.07 | Omeprazole versus famotidine in the healing and relapse of duodenal ulcer. ( Dasarathy, S; Misra, SC; Sharma, MP, 1993) |
| "The purpose of the work was an evaluation of duodenal ulcer recurrence rate in patients with a history of at least two years of ulcer treated during one year with the preparation Ulfamid (famotidine) Krka in a maintenance dose of 20 mg before sleep." | 5.07 | [Clinical evaluation of one-year controlled studies of duodenal ulcer recurrence rate in patients treated with the preparation Ulfamid]. ( Gabryelewicz, A; Jaroszewicz-Heigelmann, H; Kosidło, S; Marlicz, K, 1993) |
| " Double-blind comparative studies with a beta-blocker, famotidine, in gastric ulcer (study 1) and in duodenal ulcer (study 2) were conducted." | 5.07 | [Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer]. ( Ogawa, N, 1992) |
| "We monitored 24-hour gastric acidity in 16 resistant duodenal ulcer patients treated with ranitidine 300 mg hora somni (9 cases) and famotidine 40 mg hora somni (7 cases) for 3 months." | 5.07 | Duration of acid suppression in H2-antagonist nonresponders. ( Celle, G; Cutela, P; Mela, GS; Mele, MR; Savarino, V; Zentilin, P, 1992) |
| "The efficacy and safety of omeprazole, in 241 patients with active recurrent duodenal ulcer from 21 Italian centres, was studied in a multicentre double-blind randomized trial comparing 20 mg omeprazole o." | 5.07 | Omeprazole versus famotidine in the short-term treatment of duodenal ulcer disease. ( Annibale, B; Cassetta, MR; Delle Fave, G; Franceschi, M; Quatrini, M; Torsoli, A, 1992) |
| "In a double blind, multicenter, parallel group clinical trial in patients with symptomatic duodenal ulcers, 129 patients were randomized to receive either omeprazole 20 mg once daily (n = 65) or famotidine 40 mg once daily (n = 64) for 2 weeks, and if the ulcers were not healed, for a total of 4 weeks." | 5.07 | Comparative study of omeprazole and famotidine in the treatment of duodenal ulcer. ( Babu, S; Chaubal, C; Kumar, TR; Naidu, MU; Prasad, R; Reddy, DN; Shobha, JC; Subhash, S, 1992) |
| "In a two center open uncontrolled clinical trial, the efficacy of a single evening dose of 40 mg famotidine (Ulcusan) was studied in a total of 37 patients (20 with chronic duodenal ulcers, 9 with recurring and 8 with acute gastric ulcers)." | 5.07 | [Therapy of peptic ulcers with famotidine. Report of experiences with an open clinical study]. ( Dragosics, B; Okulski, G; Weiss, W, 1992) |
| "In a prospective, randomized, single-blind, single-center, controlled study, we compared the effectiveness of single doses of cimetidine 800 mg, ranitidine 300 mg, and famotidine-40 mg given either as evening or morning doses for duodenal ulcer healing." | 5.07 | Morning versus evening dose: a comparison of three H2-receptor blockers in duodenal ulcer healing. ( Affarah, HB; Khasawneh, SM, 1992) |
| " In this 2:1 randomized, double-blind, multicentre trial lansoprazole 30 mg am was compared to 40 mg famotidine nocte in 264 out-patients suffering from uncomplicated duodenal ulcer." | 5.07 | Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration. ( Grymbowski, T; Hennig, U; Hotz, J; Kleinert, R; Schwarz, JA, 1992) |
| "A randomized controlled study comparing once-a-day morning and once-a-day bedtime administration of 40 mg famotidine in treating duodenal ulcers was carried out in 99 Japanese patients." | 5.07 | A comparative study of once-a-day morning and once-a-day bedtime administration of 40 mg famotidine in treating duodenal ulcers. ( Arita, M; Hoshiko, K; Iida, M; Maeda, K; Okada, M; Okada, Y; Sakamoto, K; Sakurai, T; Yao, T, 1992) |
| "We evaluated the circadian pattern of gastric acidity by prolonged intraluminal pHmetry in 15 "responder" and 10 "nonresponder" duodenal ulcer patients after nocturnal administration of placebo, ranitidine, and famotidine." | 5.07 | Prolonged gastric pH monitoring in responder and nonresponder duodenal ulcer patients: response to placebo and to H2-blocker administration. ( Arossa, W; De la Pierre, M; Masoero, G; Rossanino, A, 1991) |
| "5 mg twice daily), amantadine (100 mg nocte), or with the H2 blockers cimetidine (800 mg nocte), and famotidine (40 mg nocte) in 124 patients with endoscopically proven duodenal ulcer (DU)." | 5.07 | Dopamine agonists prevent duodenal ulcer relapse. A comparative study with famotidine and cimetidine. ( Duvnjak, M; Jagic, V; Mise, S; Petek, M; Rotkvic, I; Rucman, R; Seiwerth, S; Sikiric, P; Suchanek, E; Zjacic-Rotkvic, V, 1991) |
| "Famotidine, a new H2 antagonist in a dose of 40 mg qhs was tried in a clinical trial for the treatment of duodenal ulcer in 25 patients and compared with other H2 antagonists." | 5.06 | Treatment of acute duodenal ulcers with famotidine and its comparison with other H2 blockers. ( Akhtar, MA; Khan, MA; Rashid, P, 1990) |
| " We used this technique to evaluate the effects on gastric acidity of placebo, ranitidine 150mg, famotidine 20mg and nizatidine 150mg in fifteen patients with healed duodenal ulcer." | 5.06 | Continuous intragastric pH monitoring: a real progress in the assessment of antisecretory drugs. ( Savarino, V, 1990) |
| "In a double-blind randomised trial, 40 patients with active gastric or duodenal ulcer were treated with a single nocturnal dose of famotidine 40 mg or ranitidine 300 mg for 4 to 8 weeks." | 5.06 | Double-blind comparison of the safety and efficacy of famotidine with ranitidine in patients with endoscopically diagnosed peptic ulcer. ( Bowalekar, SK; Jha, RJ; Nanivadekar, SA; Navani, SR; Oke, VG; Patel, HD; Raghu, CN; Sawant, PD; Shroff, CP, 1990) |
| "A multicenter, open study was designed to evaluate the efficacy and tolerability of a novel and potent H2 receptor antagonist, Famotidine, in the treatment of duodenal ulcer." | 5.06 | [Famotidine in the treatment of duodenal peptic ulcer]. ( Berrios, J; Bussalleu, A; Espejo, H; Espinoza, R; Farfán, G; Galarza, J; Guerra, J; Nago, A; Simich, C; Valladares, G, 1990) |
| "The efficacy and safety of famotidine and ranitidine in the treatment of active duodenal ulcer were compared in a multicentre, randomized, double-blind study." | 5.06 | A multicentre, randomized, double-blind study comparing nocte famotidine or ranitidine for the treatment of active duodenal ulceration. ( Alcalá Santaella, R; Alvárez, E; Castellanos, P; Guardia, J; Guarner, L; Ortiz, J; Pajares, J; Pesquera, R; Piqué, J; Pita, L, 1989) |
| "Six asymptomatic, non-smoking men with endoscopically proven duodenal ulcer disease received single nocturnal doses of placebo, 40 mg famotidine and 300 mg ranitidine each for 1 week prior to serial measurement of pH, peptic activity and serum gastrin concentrations over 24 h and of acid output." | 5.06 | A single night-time dose of famotidine is equivalent to ranitidine in decreasing 24-hour gastric acidity in asymptomatic duodenal ulcer subjects. ( Kirdeikis, J; Marriage, B; Pinchbeck, BR; Prat, A; Thomson, AB; Zuk, L, 1989) |
| "Famotidine (40 mg) and 800 mg cimetidine as single night-time doses were compared in a randomized, double-blind, multicentre study of acute treatment for duodenal ulceration." | 5.06 | Single night-time doses of 40 mg famotidine or 800 mg cimetidine in the treatment of duodenal ulcer. ( Booth, SN; Cochran, KM; Cottrell, J; Crowe, J; Dickinson, RJ; Kennedy, NP; Lee, FI; Mann, SG, 1989) |
| "The efficacy and safety of famotidine and ranitidine in the treatment of active duodenal ulcer were compared in a multicenter, randomized double-blind study." | 5.06 | A multicenter, randomized, double-blind study comparing once-daily bedtime administration of famotidine and ranitidine in the short-term treatment of active duodenal ulcer. ( Alcalá Santaella, R; Alvárez, E; Castellanos, P; Guardia, J; Guarner, L; Ortiz, J; Pajares, J; Pesquera, R; Pique, J; Pita, L, 1989) |
| "The efficacy and safety of famotidine and ranitidine in the treatment of active duodenal ulcer were compared in a multicenter, randomized double-blind study." | 5.06 | A multicenter, randomized, double-blind study comparing a daily bedtime administration of famotidine and ranitidine in short-term treatment of active duodenal ulcer. ( Alcalá-Santaella, R; Alvárez, E; Castellanos, P; Guardia, J; Guarner, L; Ortiz, J; Pajares, J; Pesquera, R; Piqué, J; Pita, L, 1989) |
| "This multicentric, double-blind and prospective study, which involved 41 French Gastroenterology Units, was designed to evaluate the efficacy and safety of famotidine, 40 mg at bedtime, compared to single dose ranitidine, 300 mg, in promoting the healing of duodenal ulcer." | 5.06 | [Comparative efficacy of famotidine and ranitidine in the treatment of acute-phase duodenal ulcer. A French comparative therapeutic trial]. ( Delvaux, M; Hagège, CG; Ribet, A, 1989) |
| "In a double-blind multicenter trial, 100 patients with active duodenal ulcer were treated with a single nocturnal dose of famotidine 40 mg or ranitidine 300 mg." | 5.06 | Treatment of active duodenal ulcers with famotidine. A double-blind comparison with ranitidine. ( Gugler, R; Rohner, HG, 1986) |
| "Famotidine, a new long-acting histamine (H2)-receptor antagonist, has recently been shown to be more effective than placebo in healing active duodenal ulcer." | 5.06 | A multicenter, randomized, double-blind study comparing famotidine with ranitidine in the treatment of active duodenal ulcer disease. ( McCullough, AJ, 1986) |
| "One hundred and thirty-two patients with endoscopically confirmed duodenal ulcers were entered into a 4-6-week double-blind trial of famotidine (Fm) and ranitidine (Rn)." | 5.06 | Comparison of famotidine 40 mg with ranitidine 300 mg at night in short-term duodenal ulcer healing. A South African multicentre study. ( Marks, IN; Wright, JP, 1987) |
| "A multicenter, double-blind, randomized, controlled study was conducted in 234 duodenal ulcer patients to compare the efficacy and safety of the H2-receptor antagonists famotidine and ranitidine in the treatment of duodenal ulcer." | 5.06 | Comparison of once-daily bedtime administration of famotidine and ranitidine in the short-term treatment of duodenal ulcer. A multicenter, double-blind, controlled study. ( Boero, A; Camarri, E; Crespi, M; De Pretis, G; Dobrilla, G; Fontana, G; Ideo, G; Manenti, F; Marenco, G; Piazzi, L, 1987) |
| " The effects have been compared of ranitidine and famotidine on PGE2 content in duodenal ulcer patients." | 5.06 | Action of famotidine and ranitidine on prostaglandin E2 (PGE2) content of fundic and duodenal mucosa in duodenal ulcer patients. ( Carlei, F; D'Alessandro, MD; Lezoche, E; Lomanto, D; Mariani, P; Martelli, A; Nardovino, M; Speranza, V; Vagni, V, 1987) |
| "Eight patients with previous duodenal ulcer in symptomatic remission underwent continuous intraluminal pH monitoring on five separate occasions to compare the effects on 24-h intragastric acidity of placebo, 300 mg ranitidine at night, 150 mg ranitidine twice daily, 40 mg famotidine at night, and 20 mg famotidine twice daily." | 5.06 | Once and twice daily doses of H2 antagonists revisited, using continuous intragastric pH monitoring. ( Celle, G; Fera, G; Mela, GS; Savarino, V; Scalabrini, P; Sumberaz, A; Zentilin, P, 1988) |
| "The effect of administering low doses of famotidine or ranitidine alone or in combination with an M1-receptor-selective antagonist, pirenzepine, on night intragastric acidity was evaluated in 16 active duodenal ulcer patients to verify 1) whether anticholinergics and H2-antagonists have a synergic effect on inhibition of night gastric acidity, and 2) whether patients with vagal hypertone are more sensitive to anticholinergics than the remainder of the duodenal ulcer population." | 5.06 | Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients? ( Clausi, GG; Farinelli, M; Farroni, F; Fiorucci, S; Morelli, A; Pelli, MA; Santucci, L, 1988) |
| "The efficacy of famotidine, a potent new long-acting H2 receptor antagonist, was compared with cimetidine in 78 patients with endoscopically proven acute duodenal ulcers." | 5.06 | Famotidine versus cimetidine in the treatment of acute duodenal ulcer. Double-blind, randomized clinical trial comparing nocturnal administration of 40 mg famotidine to 800 mg cimetidine. ( Fölsch, UR; Hartmann, H, 1988) |
| "Famotidine was compared to ranitidine in a short-term study on the treatment of duodenal ulcer." | 5.06 | Famotidine in the short and long-term treatment of duodenal ulcer. ( Bettarello, A; Coelho, LG; de Paula Castro, L; Dias Avelar, C; Eisig, JN; Massuda, HK; Villalobos, JJ; Zaterka, S, 1988) |
| "An integrated analysis of the fifteen published prospective multicenter studies that have examined the safety and efficacy of famotidine for the short-term (13) and maintenance (2) therapy of duodenal ulcer included over 2,600 patients." | 5.06 | Famotidine in the management of duodenal ulcer: an analysis of multicenter findings worldwide. ( Reynolds, JC, 1988) |
| "In order to assess whether dinnertime administration of a once daily dose of famotidine is more advantageous than a bedtime dose in suppressing evening and nocturnal gastric acidity, we gave nine patients with a past history of duodenal ulcer in double-blind, randomized fashion either (1) placebo at 6 p." | 5.06 | A comparison of the effects on intragastric acidity of bedtime or dinnertime administration of a once daily dose of famotidine. ( Celle, G; Fera, G; Mela, GS; Savarino, V; Scalabrini, P; Sumberaz, A; Zentilin, P, 1988) |
| "Three double blind crossover studies were carried out to assess the ability of primed infusions of famotidine to raise intragastric pH over 24 hours in 12 duodenal ulcer patients." | 5.06 | Continuous intravenous infusions of famotidine maintain high intragastric pH in duodenal ulcer. ( Kaufman, D; Kempf, M; Merki, HS; Neumann, J; Röhmel, J; Walt, RP; Witzel, L, 1988) |
| "In 11 duodenal ulcer patients, the antisecretory effects of bedtime famotidine 40 mg were compared to those obtained with ranitidine 300 mg and placebo by means of continuous 24-hour intragastric pH monitoring." | 5.06 | Continuous 24-hour intragastric pH monitoring in the evaluation of the effect of a nightly dose of famotidine, ranitidine and placebo on gastric acidity of patients with duodenal ulcer. ( Celle, G; Di Timoteo, E; Magnolia, MR; Mela, GS; Savarino, V; Scalabrini, P, 1987) |
| "185 patients with endoscopically proven duodenal ulcers were randomly allocated to treatment with either famotidine 40 mg nocte, 20 mg bid, 40 mg bid or ranitidine 150 mg bid for 2-8 weeks in a prospective double-blind study." | 5.05 | [Famotidine versus ranitidine in the acute treatment of duodenal ulcer. A multicenter comparative study in Germany]. ( Dammann, HG; Jakob, G; Miederer, SE; Müller, P; Ottenjann, R; Paul, F; Scholten, T; Schütz, E; Seifert, E; Simon, B, 1985) |
| "One-hundred and eight-three patients with endoscopically proven duodenal ulcers, enrolled in this prospective, double-blind study, were randomly allocated to receive famotidine 40 mg once at night, 20 mg twice daily, 40 mg twice daily, or ranitidine 150 mg twice daily for 2-8 weeks." | 5.05 | Famotidine versus ranitidine for the short-term treatment of duodenal ulcer. ( Dammann, HG; Jakob, G; Miederer, SE; Müller, P; Ottenjann, R; Paul, F; Scholten, T; Schütz, E; Seifert, E; Simon, B, 1985) |
| "The new H2 receptor antagonist, famotidine, has been tested in open and double-blind studies in over 2,000 acute duodenal or gastric ulcer patients as well as in the maintenance of chronic duodenal ulcer patients." | 5.05 | Famotidine in the treatment of gastric and duodenal ulceration: overview of clinical experience. ( Bianchi Porro, G, 1985) |
| "The aim of this study was to gain experience concerning efficacy and safety of famotidine, the new H2-receptor antagonist, for the maintenance of duodenal ulcer disease." | 5.05 | [Famotidine versus placebo in prevention of the recurrence of duodenal ulcer disease. A multicenter study in Germany, Austria and Italy]. ( Baglioni, A; Barbara, L; Bianchi-Porro, G; Blasi, A; Canelli, B; Cheli, R; Dal Monte, R; Dammann, HG; Francavilla, A; Hentschel, E, 1985) |
| "Although anti-inflammatory doses of ibuprofen are very effective in treating the signs and symptoms of osteoarthritis (OA), they come with an increased risk for gastrointestinal damage which can limit their use and decrease patient adherence to therapy." | 4.90 | Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials. ( Bello, AE; Grahn, AY; Holt, RJ; Kent, JD; Rice, P, 2014) |
| " Early indications that acid suppression was effective in the management of NSAID-related peptic ulcers came from studies showing that gastric ulcers could be healed by omeprazole in patients who continued to take NSAIDs." | 4.80 | Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression. ( Armstrong, D; Lad, R, 1999) |
| "The aim was to compare the clinical efficacy of lansoprazole with the efficacies of ranitidine and famotidine in order to rank this drug in the hierarchy of duodenal ulcer treatments." | 4.79 | Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. ( Agostini, H; Lemaire, M; Poynard, T, 1995) |
| "The clinical efficacy of famotidine has been clearly shown in the short- and long-term treatment of a number of acid-related diseases such as duodenal and gastric ulcer as well as in the acute management of reflux esophagitis." | 4.78 | Clinical efficacy of famotidine in the treatment of acid-related diseases: an overview. ( Dammann, HG, 1990) |
| "The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of osteoarthritis and rheumatoid arthritis and to decrease the risk of developing gastric and duodenal ulcers in patients at risk for NSAID-associated ulcers." | 3.77 | A fixed-dose combination ibuprofen and famotidine (Duexis). ( , 2011) |
| "To study the effects of growth factors on experimental duodenal ulcer healing in indomethacin-treated rats." | 3.72 | Effect of exogenous administration of transforming growth factor-beta and famotidine on the healing of duodenal ulcer under the impact of indomethacin. ( Arceiz, E; Lanas, A; Ortego, J; Pérez-Aisa, A; Sainz, R; Sopeña, F, 2003) |
| "Duodenal ulcer was induced in male Wistar rats with acetic acid." | 3.71 | [Effect of exogenous administration of platelet-derived growth factor and epidermal growth factor on duodenal ulcer healing in rats treated with indomethacin]. ( Arceiz Gonzalo, E; Lanas Arbeloa, A; Ortego Díez De Retana, J; Pérez Aisa, A; Sainz Samitier, R; Sopeña Biarge, F, 2002) |
| " pylori-infected patients with duodenal ulcer were treated with either omeprazole or famotidine plus two antibiotics for 2 wk." | 3.70 | The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country. ( Acevedo, C; Duarte, I; Figueroa, C; Fuster, F; Giancaspero, R; Hola, K; Rollan, A; Schulz, M, 2000) |
| "24-h monitoring of pH of the gastric juice demonstrated that three-component therapy consisting of quamatel (20 mg/day, metronidazole (500 mg 4 times a day), amoxicillin (750 mg 3 times a day) maintains the level of intragastric acidity optimal for quick scarring of duodenal ulcer defect and led to eradication of H." | 3.70 | [24-hour monitoring of gastric juice pH in assessment of anti-ulcer treatment]. ( Andreev, NG; Ismailova, MZ; Maev, IV; Romashkina, MA; Val'tsova, ED, 2000) |
| ") inhibited mepirizole-induced duodenal ulcers." | 3.69 | YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats. ( Akuzawa, S; Ito, H; Kamato, T; Kobayashi, A; Miyata, K; Nagakura, Y; Nishida, A; Takinami, Y; Yamano, M; Yuki, H, 1994) |
| "The gastrojet, a closed loop pH feedback infusion pump capable of maintaining intragastric pH at a target value by infusing H2 blockers at variable rates, was used to assess factors influencing the quantity of famotidine required to maintain intragastric pH above 4 for 24 hours in 34 fed patients with duodenal ulcers." | 3.69 | Maintenance of intragastric pH > 4 with famotidine in duodenal ulcer patients: factors influencing drug requirements. ( Deharvengt, MC; Delchier, JC; Elouaer Blanc, L; Roudot-Thoraval, F; Stanescu, L, 1994) |
| "A 51-year-old obese woman with a duodenal ulcer developed symptomatic, famotidine-induced hepatitis." | 3.69 | Hepatitis following treatments with famotidine and then cimetidine. ( Davis, RL; Egli, D; Hashimoto, F, 1994) |
| "The combination of sucralfate (SUC) and famotidine (FAM) at subtherapeutic dose on cysteamine-induced duodenal ulcers (3 x 250 mg/kg) in female rats was studied." | 3.69 | The effect of the combination therapy with sucralfate and famotidine on experimentally induced duodenal ulcers in rats. ( Zupancic, P, 1996) |
| "Healing-promoting actions of KU-1257 (N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy]propyl]urea, CAS 120958-90-9) were investigated in chronic gastric and duodenal ulcer models induced by acetic acid in rats and the effects were compared with those of famotidine and roxatidine acetate by gross or histological evaluation." | 3.68 | Healing-promoting action of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy]propyl]urea with dual action on chronic gastric and duodenal ulcers induced by acetic acid in rats. ( Aijima, H; Hamada, K; Nishino, K; Sekiguchi, H; Taga, F; Uchida, H, 1993) |
| "The studies of microsomal liver enzyme activity by means of a respiratory test with 14C-aminopyrine (ABT) were carried out in 20 patients with duodenal ulcer treated for eight weeks with famotidine." | 3.68 | [Evaluation of microsomal enzyme function in the liver in patients with duodenal ulcer treated with famotidine]. ( Grzeszczak, W; Piotrowska, E; Piotrowski, J, 1993) |
| "The liver microsomal enzymes activity was measured by aminopyrine breath test in 20 subjects with duodenal ulcer disease treated with famotidine for 8 weeks." | 3.68 | [Assessment of microsomal enzyme function in liver of patients with duodenal ulcer treated with famotidine]. ( Grzeszczak, W; Piotrowska, E; Piotrowski, J, 1993) |
| "Fourteen patients with duodenal ulcers and eight healthy volunteers were examined to measure interdigestive gastroduodenal motility and plasma motilin." | 3.68 | Gastric acid inhibits antral phase III activity in duodenal ulcer patients. ( Horikoshi, T; Kawamura, O; Kikuchi, K; Kusano, M; Matsuzaki, T; Nishioka, T; Sekiguchi, T, 1993) |
| "In this open trial, 25 patients with identified duodenal ulcers were given long-term therapy of a single evening dose of 20 mg famotidine." | 3.68 | [Prevention of the recurrence of duodenal ulcer with famotidine. Report of experiences with long-term therapy in an open clinical study]. ( Judmaier, G, 1992) |
| " Gastric and duodenal ulcerations induced by cold stress plus indomethacin, restraint and water immersion stress, pylorus ligation or cysteamine were also inhibited by pretreatment with 2-B4O." | 3.68 | Effect of an endogenous satiety substance, 2-buten-4-olide, on gastric acid secretion and experimental ulceration in rats. ( Arai, I; Muramatsu, M; Oomura, Y; Otomo, S; Shiraishi, T; Usuki-Ito, C, 1990) |
| "Fifty three patients with duodenal ulcer were treated with 40 mg of famotidine at bed time." | 3.67 | A single nocte dose of famotidine in the treatment of duodenal ulcer. ( Ahmad, W; Qureshi, H; Zuberi, SJ, 1989) |
| "The aim of this study was to evaluate the clinical efficacy of short and long-term treatment with famotidine 40 mg/daily at bed time in duodenal ulcer disease." | 3.67 | [Famotidine in the short and long term treatment of duodenal ulcer: clinical and physiopathologic study]. ( Dal Santo, L; Di Mario, F; Gottardello, L; Grassi, SA; Naccarato, R; Pasqualetti, P; Tessaro, P; Vianello, F; Vio, A, 1989) |
| "1 The effects of the new H2-receptor antagonist famotidine, administered orally, on gastric secretion and emptying as well as on experimentally-induced gastric and duodenal ulcers were studied in the rat." | 3.67 | Antisecretory and antiulcer effect of the H2-receptor antagonist famotidine in the rat: comparison with ranitidine. ( Scarpignato, C; Tramacere, R; Zappia, L, 1987) |
| "The H2-receptor antagonists mifentidine, famotidine, cimetidine and ranitidine were examined for their ability to prevent the duodenal ulcer caused by mepirizole (250 mg/kg p." | 3.67 | Effect of mifentidine on mepirizole-induced duodenal ulcer in the rat. ( Brambilla, A; De Paoli, AM; Ghiorzi, A; Giachetti, A, 1987) |
| "Data from several sources are used to quantify the expected direct medical costs of a recently healed duodenal ulcer patient prescribed an H2-antagonist (famotidine) for a 6-month period." | 3.67 | The cost-effectiveness of maintenance therapy for duodenal ulceration with an H2-antagonist. ( Fox, N; Jacobs, J; Morton, RE, 1988) |
| "The effect of a single bedtime dose of famotidine 40 mg on gonadal function was studied in 8 male duodenal ulcer patients." | 3.67 | Famotidine has no significant effect on gonadal function in man. ( Bessarione, D; Celle, G; Giusti, M; Magnolia, MR; Percario, G; Savarino, V; Scalabrini, P, 1988) |
| "Healing processes of duodenal ulcers induced by mepirizole and effects of several drugs on the ulcer healing were studied in rats." | 3.66 | Effects of antiulcer agents on healing of mepirizole-induced duodenal ulcers in rats. ( Ishihara, Y; Okabe, S, 1983) |
| "Famotidine was administered after lunch and before sleep, and the others were after breakfast and dinner." | 2.71 | Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. ( Furuta, T; Miura, S; Okudaira, K; Shirai, N; Sugimoto, M, 2005) |
| "Famotidine increased the lower esophagus sphincter pressure from the initial 2." | 2.68 | [The effect of cimetidine and famotidine on esophageal motility]. ( Paradowski, L; Salomon, A; Szelag, A, 1996) |
| "for the prevention of duodenal ulcer recurrence." | 2.67 | A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse. ( Barbara, L; Bianchi Porro, G; Blasi, A; Bovero, E; Capurso, L; Cheli, R; Corinaldesi, R; Koch, M; Lazzaroni, M; Mangiameli, A, 1991) |
| "Famotidine appears to be an effective and safe once-a-day therapy for the treatment of acute duodenal ulcer disease." | 2.66 | A multicenter, double-blind, randomized, placebo-controlled comparison of nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer disease. ( Berman, R; Gitlin, N; Mantell, G; McCullough, AJ; Smith, JL, 1987) |
| " In view of possible increased patient compliance with a simplified dosage regimen, famotidine 40 mg h." | 2.66 | Review of an extensive worldwide study of a new H2-receptor antagonist, famotidine, as compared to ranitidine in the treatment of acute duodenal ulcer. ( Bianchi Porro, G; Cook, T; Dicenta, C; Humphries, TJ, 1987) |
| "H2-blockers reduce the annual recurrence from nearly 70% to about 25%." | 2.66 | H2-receptor antagonists and duodenal ulcer recurrence: analysis of efficacy and commentary on safety, costs, and patient selection. ( Freston, JW, 1987) |
| " Therefore, the two dosing schedules of each H2 antagonist increased intragastric pH differently, but both the half and the standard large regimens produced similar overnight virtual anacidity." | 2.66 | Overnight comparable anacidity by standard large and half-single bedtime doses of H2 antagonists in duodenal ulcer patients: a clinical pharmacological study. ( Celle, G; Fera, G; Mela, GS; Savarino, V; Scalabrini, P; Sumberaz, A; Zentilin, P, 1988) |
| "Ibuprofen/famotidine was generally well tolerated, with a tolerability profile consistent with those established for the individual agents." | 2.49 | Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy. ( Deeks, ED, 2013) |
| " This study was undertaken to determine whether patients with chronic use of H2-receptor antagonists (HRA) had demonstrable decreases in bone mineral density (BMD)." | 1.30 | Bone mineral density in patients taking H2-receptor antagonist. ( Adachi, Y; Iso, Y; Kitano, S; Matsumata, T; Shiota, E; Yoh, R, 1998) |
| "93 patients (19%) were treated for abdominal pain where no diagnosis had been reached or who had only a diagnosis of gastritis on endoscopy." | 1.29 | Long term acid suppressing treatment in general practice. ( Jacyna, MR; Levi, AJ; Miller, RJ; O'Reilly, S; Ross, J; Ryder, SD, 1994) |
| "None of these 15 patients had a recurrence 3 months later." | 1.28 | The histological maturity of regenerating mucosa of healed duodenal ulcer and ulcer recurrence after treatment with H2-antagonist. ( Liao, CH; Pan, S, 1990) |
| "Operative management also reduces recurrence rates, which, however, are commoner in patients coming to surgery nowadays." | 1.28 | High doses of ranitidine in maintenance therapy of duodenal ulcer patients. ( Lee, FI, 1990) |
| " The therapy was prolonged for two years with the same dosage at the beginning and later with half doses without any relapse and secondary effects." | 1.28 | [Duodenal ulcer, study of gastric secretion and rational treatment with famotidine in different doses]. ( Idotta, G; Morucci, P; Santoro, E; Scutari, F, 1989) |
| "Famotidine is a potent H2 receptor antagonist containing a thiazole ring structure, thus differing chemically from cimetidine and ranitidine." | 1.27 | Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology. ( , 1987) |
| " The expected antisecretory effect of a particular dosage regimen in patients with duodenal ulcer can be predicted mathematically from data derived from studies in normal volunteers." | 1.27 | Comparison of the effects of gastric antisecretory agents in healthy volunteers and patients with duodenal ulcer. ( Burget, DW; Howden, CW; Hunt, RH; Jones, DB, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 66 (39.05) | 18.7374 |
| 1990's | 72 (42.60) | 18.2507 |
| 2000's | 23 (13.61) | 29.6817 |
| 2010's | 7 (4.14) | 24.3611 |
| 2020's | 1 (0.59) | 2.80 |
| Authors | Studies |
|---|---|
| Wong, GLH | 1 |
| Lau, LHS | 1 |
| Ching, JYL | 1 |
| Tse, YK | 1 |
| Ling, RHY | 1 |
| Wong, VWS | 1 |
| Chiu, PWY | 1 |
| Lau, JYW | 1 |
| Chan, FKL | 1 |
| Deeks, ED | 1 |
| Nichitaĭlo, ME | 1 |
| Bello, AE | 3 |
| Kent, JD | 2 |
| Grahn, AY | 2 |
| Rice, P | 1 |
| Holt, RJ | 2 |
| Laine, L | 1 |
| Kivitz, AJ | 1 |
| Schiff, MH | 1 |
| Taha, AS | 3 |
| Chan, FK | 1 |
| Grinevich, VB | 2 |
| Uspenskiĭ, IuP | 1 |
| Shabanova, GZh | 1 |
| Sablin, OA | 2 |
| Shcherbina, NN | 1 |
| Uspenskiĭ, IuL | 1 |
| Ohsawa, T | 1 |
| Hirata, W | 1 |
| Higichi, S | 1 |
| Pérez-Aisa, A | 1 |
| Sopeña, F | 1 |
| Arceiz, E | 1 |
| Ortego, J | 1 |
| Sainz, R | 1 |
| Lanas, A | 1 |
| Kirika, NV | 1 |
| Bodrug, NI | 1 |
| Butorov, IV | 1 |
| Butorov, SI | 1 |
| Korukov, B | 1 |
| Ognianov, S | 1 |
| Kostadinova, R | 1 |
| Gerzilov, P | 1 |
| Ivanov, A | 1 |
| Iarŭmov, N | 1 |
| Okudaira, K | 1 |
| Furuta, T | 1 |
| Shirai, N | 1 |
| Sugimoto, M | 1 |
| Miura, S | 1 |
| Guseĭnzade, MG | 1 |
| Vakhrushev, IaM | 2 |
| Muravtseva, OV | 2 |
| Ji, F | 1 |
| Chen, JY | 1 |
| Chen, JX | 1 |
| Ishihara, Y | 1 |
| Okabe, S | 1 |
| Shiratori, K | 1 |
| Watanabe, S | 1 |
| Maruyama, M | 1 |
| Itoh, Y | 1 |
| Adachi, H | 1 |
| Kurokawa, K | 1 |
| Takeuchi, T | 1 |
| Mori, H | 1 |
| Masci, E | 1 |
| Colombo, E | 1 |
| Testoni, PA | 1 |
| Fanti, L | 1 |
| Guslandi, M | 1 |
| Tittobello, A | 1 |
| Delchier, JC | 2 |
| el Amine, I | 1 |
| Roudot-Thoraval, F | 2 |
| Elouaer-Blanc, L | 2 |
| Lamarque, D | 1 |
| Stanescu, L | 2 |
| Maculotti, L | 1 |
| Pradella, P | 1 |
| Gschwantler, M | 2 |
| Weiss, W | 4 |
| Penka, G | 1 |
| Zirm, B | 1 |
| Stupnicki, T | 1 |
| Spath, P | 1 |
| Sobhani, I | 1 |
| Chastang, C | 1 |
| De Korwin, JD | 1 |
| Lamouliatte, H | 1 |
| Mégraud, F | 1 |
| Guerre, J | 1 |
| Dominguez, HL | 1 |
| Freston, JW | 2 |
| Arizón Deza, P | 1 |
| García Tenorio, A | 1 |
| Gonzalo Til, A | 1 |
| Manero Ruiz, I | 1 |
| Mur Lalueza, MJ | 1 |
| Pascual Parrilla, MS | 1 |
| Casini, A | 2 |
| Mari, F | 2 |
| Surrenti, C | 2 |
| Lin, JT | 1 |
| Wang, JT | 1 |
| Wu, MS | 1 |
| Lee, WY | 1 |
| Yang, JC | 1 |
| Wang, TH | 2 |
| Nishida, A | 1 |
| Takinami, Y | 1 |
| Yuki, H | 1 |
| Kobayashi, A | 1 |
| Akuzawa, S | 1 |
| Kamato, T | 1 |
| Ito, H | 1 |
| Yamano, M | 1 |
| Nagakura, Y | 1 |
| Miyata, K | 1 |
| Matsunaga, Y | 1 |
| Yamamoto, O | 1 |
| Ueki, S | 1 |
| Haga, N | 1 |
| Mizusawa, F | 1 |
| Mizumoto, A | 1 |
| Sano, I | 1 |
| Itoh, Z | 1 |
| Deharvengt, MC | 1 |
| Elouaer Blanc, L | 1 |
| Sekiguchi, H | 1 |
| Hamada, K | 1 |
| Aijima, H | 1 |
| Taga, F | 1 |
| Uchida, H | 1 |
| Nishino, K | 1 |
| Hashimoto, F | 1 |
| Davis, RL | 1 |
| Egli, D | 1 |
| Reynolds, JC | 3 |
| Schoen, RE | 1 |
| Maislin, G | 1 |
| Zangari, GG | 1 |
| Ryder, SD | 1 |
| O'Reilly, S | 1 |
| Miller, RJ | 1 |
| Ross, J | 1 |
| Jacyna, MR | 1 |
| Levi, AJ | 1 |
| Pizzigallo, AM | 1 |
| Bertol, E | 1 |
| Misra, SC | 1 |
| Dasarathy, S | 1 |
| Sharma, MP | 1 |
| Piotrowska, E | 2 |
| Piotrowski, J | 2 |
| Grzeszczak, W | 2 |
| Gabryelewicz, A | 1 |
| Kosidło, S | 1 |
| Marlicz, K | 1 |
| Jaroszewicz-Heigelmann, H | 1 |
| Kusano, M | 1 |
| Sekiguchi, T | 1 |
| Nishioka, T | 1 |
| Kawamura, O | 1 |
| Kikuchi, K | 1 |
| Matsuzaki, T | 1 |
| Horikoshi, T | 1 |
| Poynard, T | 1 |
| Lemaire, M | 1 |
| Agostini, H | 1 |
| Hudson, N | 2 |
| Hawkey, CJ | 2 |
| Swannell, AJ | 1 |
| Trye, PN | 1 |
| Cottrell, J | 3 |
| Mann, SG | 3 |
| Simon, TJ | 1 |
| Sturrock, RD | 2 |
| Russell, RI | 2 |
| Zupancic, P | 1 |
| Goh, KL | 1 |
| Navaratnam, P | 1 |
| Peh, SC | 1 |
| Wong, NW | 1 |
| Chuah, SY | 1 |
| Rahman, NA | 1 |
| Lo, YL | 1 |
| Goenka, MK | 1 |
| Kochhar, R | 1 |
| Chakrabarti, A | 1 |
| Kumar, A | 1 |
| Gupta, O | 1 |
| Talwar, P | 1 |
| Mehta, SK | 1 |
| Liss, GM | 1 |
| Paradowski, L | 1 |
| Salomon, A | 1 |
| Szelag, A | 1 |
| García-Plaza, A | 1 |
| Arenas, JI | 1 |
| Belda, O | 1 |
| Diago, A | 1 |
| Domínguez, A | 1 |
| Fernández, C | 1 |
| Martín, L | 1 |
| Pallarés, A | 1 |
| Rodrigo, L | 2 |
| de la Santa, Jw | 1 |
| Pal'tsev, AI | 1 |
| Maslennikova, TA | 1 |
| Trye, P | 1 |
| Swanell, AJ | 1 |
| Grigor'ev, PI | 1 |
| Grinberg, AA | 1 |
| Toguzova, DA | 2 |
| Iakovenko, AV | 1 |
| Lopatina, IV | 1 |
| Suzuki, M | 1 |
| Mori, M | 1 |
| Miyayama, A | 1 |
| Iwai, N | 1 |
| Tsunematsu, N | 1 |
| Oonuki, M | 1 |
| Suzuki, H | 1 |
| Hibi, T | 1 |
| Ishii, H | 1 |
| Adachi, Y | 1 |
| Shiota, E | 1 |
| Matsumata, T | 1 |
| Iso, Y | 1 |
| Yoh, R | 1 |
| Kitano, S | 1 |
| Malov, IuS | 1 |
| Kulikov, AN | 1 |
| Dogăn, UB | 1 |
| Tunçer, C | 1 |
| Dursun, A | 1 |
| Kandilci, U | 1 |
| Das, UN | 1 |
| Sheptulin, AA | 1 |
| Okhlobystin, AV | 1 |
| Dragosics, B | 2 |
| Wurzer, H | 1 |
| Brandstätter, G | 1 |
| Bogachev, RS | 1 |
| Levina, ZK | 1 |
| Kulkarni, SH | 1 |
| Kshirsagar, AY | 1 |
| Lad, R | 1 |
| Armstrong, D | 1 |
| Rollan, A | 1 |
| Giancaspero, R | 1 |
| Fuster, F | 1 |
| Acevedo, C | 1 |
| Figueroa, C | 1 |
| Hola, K | 1 |
| Schulz, M | 1 |
| Duarte, I | 1 |
| Maev, IV | 1 |
| Andreev, NG | 1 |
| Val'tsova, ED | 1 |
| Romashkina, MA | 1 |
| Ismailova, MZ | 1 |
| Pleshkov, VG | 1 |
| Afanas'ev, VN | 1 |
| Ovsiankin, AV | 1 |
| Mansurova, FKh | 1 |
| Kadyrov, DM | 1 |
| Odinaev, RI | 1 |
| Ishankulova, DM | 1 |
| Liu, WZ | 1 |
| Xiao, SD | 1 |
| Hu, PJ | 1 |
| Lu, H | 1 |
| Cui, Y | 1 |
| Tytgat, GN | 1 |
| Shlevkov, BA | 1 |
| Abramova, LA | 1 |
| Rakov, AL | 1 |
| Makarov, IuS | 1 |
| Gorbakov, VV | 1 |
| Mironenko, DA | 1 |
| Golochalova, TV | 1 |
| Nikiforov, PA | 1 |
| Bazarova, MA | 1 |
| Nikitina, SA | 1 |
| Osin, VL | 1 |
| Shugurov, VA | 1 |
| Mutoh, H | 1 |
| Sugano, K | 1 |
| Pérez Aisa, A | 1 |
| Sopeña Biarge, F | 1 |
| Arceiz Gonzalo, E | 1 |
| Sainz Samitier, R | 1 |
| Ortego Díez De Retana, J | 1 |
| Lanas Arbeloa, A | 1 |
| Sato, H | 1 |
| Abe, K | 1 |
| Oshima, N | 1 |
| Kawashima, K | 1 |
| Hamamoto, N | 1 |
| Moritani, M | 1 |
| Mak, R | 1 |
| Ishihara, S | 1 |
| Adachi, K | 1 |
| Kawauchi, H | 1 |
| Kinoshita, Y | 1 |
| Tsimmerman, IaS | 1 |
| Teliaper, II | 1 |
| Ogawa, N | 1 |
| Savarino, V | 10 |
| Mela, GS | 8 |
| Zentilin, P | 5 |
| Cutela, P | 1 |
| Mele, MR | 1 |
| Celle, G | 9 |
| Delle Fave, G | 1 |
| Annibale, B | 1 |
| Franceschi, M | 1 |
| Quatrini, M | 1 |
| Cassetta, MR | 1 |
| Torsoli, A | 1 |
| Kumar, TR | 1 |
| Naidu, MU | 1 |
| Shobha, JC | 1 |
| Reddy, DN | 1 |
| Subhash, S | 1 |
| Chaubal, C | 1 |
| Prasad, R | 1 |
| Babu, S | 1 |
| Judmaier, G | 1 |
| Okulski, G | 1 |
| Brunner, H | 1 |
| Khasawneh, SM | 1 |
| Affarah, HB | 1 |
| Hotz, J | 1 |
| Kleinert, R | 1 |
| Grymbowski, T | 1 |
| Hennig, U | 1 |
| Schwarz, JA | 1 |
| Okada, M | 1 |
| Arita, M | 1 |
| Iida, M | 1 |
| Yao, T | 1 |
| Sakurai, T | 1 |
| Hoshiko, K | 1 |
| Maeda, K | 1 |
| Okada, Y | 1 |
| Sakamoto, K | 1 |
| Masoero, G | 1 |
| Rossanino, A | 1 |
| Arossa, W | 1 |
| De la Pierre, M | 1 |
| Fullarton, GM | 1 |
| Macdonald, AM | 1 |
| McColl, KE | 1 |
| Bianchi Porro, G | 5 |
| Lazzaroni, M | 3 |
| Barbara, L | 4 |
| Corinaldesi, R | 3 |
| Blasi, A | 4 |
| Mangiameli, A | 3 |
| Capurso, L | 2 |
| Koch, M | 2 |
| Cheli, R | 4 |
| Bovero, E | 3 |
| White, C | 1 |
| Smolensky, MH | 1 |
| Sanders, SW | 1 |
| Buchi, KN | 1 |
| Moore, JG | 1 |
| Inatomi, N | 1 |
| Nagaya, H | 1 |
| Takami, K | 1 |
| Shino, A | 1 |
| Satoh, H | 1 |
| Collen, MJ | 2 |
| Sheridan, MJ | 1 |
| Lipsy, RJ | 1 |
| Fennerty, B | 1 |
| Fagan, TC | 1 |
| Pan, S | 1 |
| Liao, CH | 1 |
| Akhtar, MA | 1 |
| Rashid, P | 1 |
| Khan, MA | 1 |
| Thomson, AB | 2 |
| Shibata, M | 1 |
| Yamaura, T | 1 |
| Sekine, A | 1 |
| Nishikawa, M | 1 |
| Chida, Y | 1 |
| Ohnishi, H | 1 |
| Sikiric, P | 1 |
| Rotkvic, I | 1 |
| Mise, S | 1 |
| Petek, M | 1 |
| Rucman, R | 1 |
| Seiwerth, S | 1 |
| Zjacic-Rotkvic, V | 1 |
| Duvnjak, M | 1 |
| Jagic, V | 1 |
| Suchanek, E | 1 |
| Sawant, PD | 1 |
| Nanivadekar, SA | 1 |
| Patel, HD | 1 |
| Shroff, CP | 1 |
| Oke, VG | 1 |
| Jha, RJ | 1 |
| Bowalekar, SK | 1 |
| Navani, SR | 1 |
| Raghu, CN | 1 |
| Bussalleu, A | 1 |
| Berrios, J | 1 |
| Espejo, H | 1 |
| Espinoza, R | 1 |
| Farfán, G | 1 |
| Galarza, J | 1 |
| Guerra, J | 1 |
| Nago, A | 1 |
| Simich, C | 1 |
| Valladares, G | 1 |
| Dammann, HG | 6 |
| Lee, FI | 2 |
| Arai, I | 1 |
| Usuki-Ito, C | 1 |
| Muramatsu, M | 1 |
| Otomo, S | 1 |
| Shiraishi, T | 1 |
| Oomura, Y | 1 |
| Alcalá Santaella, R | 2 |
| Guardia, J | 3 |
| Pajares, J | 3 |
| Piqué, J | 3 |
| Pita, L | 3 |
| Alvárez, E | 3 |
| Castellanos, P | 3 |
| Guarner, L | 3 |
| Ortiz, J | 3 |
| Pesquera, R | 3 |
| Pinchbeck, BR | 1 |
| Kirdeikis, J | 1 |
| Zuk, L | 1 |
| Marriage, B | 1 |
| Prat, A | 1 |
| Booth, SN | 1 |
| Cochran, KM | 1 |
| Crowe, J | 1 |
| Dickinson, RJ | 1 |
| Kennedy, NP | 1 |
| Marenco, G | 2 |
| Menardo, G | 1 |
| Pallini, P | 1 |
| Rossini, FP | 1 |
| Saggioro, A | 1 |
| Gitnick, G | 1 |
| Chen, PH | 1 |
| Wang, CY | 1 |
| Chen, CY | 1 |
| Cheng, TC | 1 |
| Tsai, YT | 1 |
| Siauw, CP | 1 |
| Yang, KC | 1 |
| Chen, GH | 1 |
| Sung, JL | 1 |
| Scalabrini, P | 7 |
| Bonifacino, G | 1 |
| Gambaro, P | 1 |
| Qureshi, H | 2 |
| Ahmad, W | 1 |
| Zuberi, SJ | 2 |
| Viver, J | 1 |
| Conchillo, F | 1 |
| Barrio, E | 1 |
| Forné, M | 1 |
| Zozaya, JM | 1 |
| Alvarez, A | 1 |
| Dieguez, P | 1 |
| Muñoz, M | 1 |
| Panés, J | 1 |
| Alcalá-Santaella, R | 1 |
| Delvaux, M | 1 |
| Hagège, CG | 1 |
| Ribet, A | 1 |
| Vio, A | 1 |
| Pasqualetti, P | 1 |
| Gottardello, L | 1 |
| Grassi, SA | 1 |
| Vianello, F | 1 |
| Dal Santo, L | 1 |
| Tessaro, P | 1 |
| Di Mario, F | 1 |
| Naccarato, R | 1 |
| Materia, A | 1 |
| Genco, A | 1 |
| Silecchia, G | 1 |
| Basso, N | 1 |
| Santoro, E | 1 |
| Morucci, P | 1 |
| Idotta, G | 1 |
| Scutari, F | 1 |
| Simon, B | 4 |
| Jakob, G | 2 |
| Miederer, SE | 2 |
| Müller, P | 3 |
| Ottenjann, R | 2 |
| Paul, F | 2 |
| Scholten, T | 2 |
| Schütz, E | 2 |
| Seifert, E | 2 |
| Smith, JL | 2 |
| Carratelli, L | 1 |
| Wilkins, A | 1 |
| Baglioni, A | 1 |
| Bianchi-Porro, G | 1 |
| Canelli, B | 1 |
| Dal Monte, R | 1 |
| Francavilla, A | 1 |
| Hentschel, E | 1 |
| Rohner, HG | 2 |
| Gugler, R | 2 |
| McCullough, AJ | 2 |
| Texter, EC | 1 |
| Navab, F | 1 |
| Mantell, G | 2 |
| Berman, R | 2 |
| Gitlin, N | 2 |
| Kimmig, JM | 2 |
| Schönekäs, H | 2 |
| Marks, IN | 1 |
| Wright, JP | 1 |
| Dicenta, C | 1 |
| Cook, T | 1 |
| Humphries, TJ | 1 |
| Dobrilla, G | 1 |
| De Pretis, G | 1 |
| Piazzi, L | 1 |
| Boero, A | 1 |
| Camarri, E | 1 |
| Crespi, M | 1 |
| Fontana, G | 1 |
| Ideo, G | 1 |
| Manenti, F | 1 |
| Scarpignato, C | 1 |
| Tramacere, R | 1 |
| Zappia, L | 1 |
| Santana, IA | 1 |
| Lanzon-Miller, S | 1 |
| Pounder, RE | 1 |
| Lezoche, E | 1 |
| Vagni, V | 1 |
| D'Alessandro, MD | 1 |
| Mariani, P | 1 |
| Carlei, F | 1 |
| Lomanto, D | 1 |
| Nardovino, M | 1 |
| Martelli, A | 1 |
| Speranza, V | 1 |
| Picciotto, A | 1 |
| Magnolia, MR | 3 |
| Brambilla, A | 1 |
| Ghiorzi, A | 1 |
| De Paoli, AM | 1 |
| Giachetti, A | 1 |
| Sumberaz, A | 3 |
| Fera, G | 3 |
| Pounder, R | 1 |
| Fiorucci, S | 1 |
| Clausi, GG | 1 |
| Farinelli, M | 1 |
| Santucci, L | 1 |
| Farroni, F | 1 |
| Pelli, MA | 1 |
| Morelli, A | 1 |
| Bonardelli, P | 1 |
| Fujita, Y | 1 |
| Fujita, R | 1 |
| Sugata, F | 1 |
| Fox, N | 1 |
| Morton, RE | 1 |
| Jacobs, J | 1 |
| Stanczak, VJ | 1 |
| Ciarleglio, CA | 1 |
| Reggio, D | 1 |
| Frattaroli, FM | 1 |
| Trentino, P | 1 |
| Oddi, A | 1 |
| Marzullo, A | 1 |
| Ponsioen, C | 1 |
| Pappalardo, G | 1 |
| Hartmann, H | 1 |
| Fölsch, UR | 1 |
| Zaterka, S | 1 |
| de Paula Castro, L | 1 |
| Villalobos, JJ | 1 |
| Massuda, HK | 1 |
| Eisig, JN | 1 |
| Dias Avelar, C | 1 |
| Coelho, LG | 1 |
| Bettarello, A | 1 |
| Giusti, M | 1 |
| Bessarione, D | 1 |
| Percario, G | 1 |
| Ahmed, W | 1 |
| Merki, HS | 1 |
| Witzel, L | 1 |
| Kaufman, D | 1 |
| Kempf, M | 1 |
| Neumann, J | 1 |
| Röhmel, J | 1 |
| Walt, RP | 1 |
| Di Timoteo, E | 1 |
| Polloni, A | 1 |
| Marchi, S | 1 |
| Greco, A | 1 |
| Cipparrone, G | 1 |
| Costa, F | 1 |
| Bellini, M | 1 |
| Maltinti, G | 1 |
| Lewis, JH | 1 |
| Walter, TA | 1 |
| Mueller, P | 1 |
| Howden, CW | 1 |
| Jones, DB | 1 |
| Burget, DW | 1 |
| Hunt, RH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Recurrent Idiopathic Gastroduodenal Ulcer Bleeding: a Double-blind Randomized Trial[NCT01180179] | Phase 4 | 228 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment[NCT00450658] | Phase 3 | 627 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment[NCT00450216] | Phase 3 | 906 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The secondary efficacy endpoint was the number of subjects with duodenal ulcer at any time throughout the 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 3 |
| Ibuprofen | 9 |
The secondary efficacy endpoint was the number of subjects with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 37 |
| Ibuprofen | 34 |
The primary efficacy endpoint was the number of subjects with upper gastrointestinal (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 40 |
| Ibuprofen | 38 |
The secondary efficacy endpoint was the number of subjects developing a NSAID-associated serious GI complication at any time throughout 6 months of treatment. A NSAID-associated serious GI complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or GI bleeding. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 0 |
| Ibuprofen | 0 |
The secondary efficacy endpoint was the number of participants with duodenal ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 8 |
| Ibuprofen | 14 |
The primary efficacy endpoint was the number of participants with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 55 |
| Ibuprofen | 52 |
The secondary efficacy endpoint was the number of participants with UGI (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 63 |
| Ibuprofen | 61 |
The secondary efficacy endpoint was the number of participants developing a NSAID-associated serious gastrointestinal complication at any time throughout 24 weeks of treatment. A NSAID-associated serious gastrointestinal complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or gastrointestinal bleeding. (NCT00450216)
Timeframe: 24 weeks
| Intervention | particpants (Number) |
|---|---|
| HZT-501 | 3 |
| Ibuprofen | 0 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
12 reviews available for famotidine and Curling Ulcer
| Article | Year |
|---|---|
Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Drug Interactions; Duodenal Ulcer; Famot | 2013 |
Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Drug Combinations; Duodenal Ulcer; Famot | 2014 |
Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Anti-Ulcer Agents; Duodenal Ulcer; Famotidin | 1995 |
Hypothesis: cis-unsaturated fatty acids as potential anti-peptic ulcer drugs.
Topics: Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Fatty Acids, Unsaturated; Helicobacter Infections; He | 1998 |
Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Gastric Juic | 1999 |
[Duodenal ulcer].
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; | 2002 |
[Effectiveness of ulcer treatment with electromagnetic radiation of extremely high frequency (EHF therapy) and some mechanism of its therapeutic action].
Topics: Anti-Ulcer Agents; Clinical Trials as Topic; Duodenal Ulcer; Electromagnetic Phenomena; Famotidine; | 2002 |
Clinical review of histamine2 receptor antagonists.
Topics: Cimetidine; Drug Interactions; Duodenal Ulcer; Famotidine; Histamine H2 Antagonists; Humans; Nizatid | 1990 |
Acid secretion and acid suppression in pathogenesis and healing of peptic ulcer disease.
Topics: Anti-Ulcer Agents; Clinical Trials as Topic; Duodenal Ulcer; Famotidine; Gastric Acid; Histamine H2 | 1990 |
Clinical efficacy of famotidine in the treatment of acid-related diseases: an overview.
Topics: Clinical Trials as Topic; Duodenal Ulcer; Esophagitis, Peptic; Famotidine; Humans; Product Surveilla | 1990 |
Famotidine in the USA: a review of efficacy studies.
Topics: Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Gastric Acid; Gastric Juice; Histamine H2 Antagonists | 1989 |
Histamine H2-receptor antagonists.
Topics: Animals; Clinical Trials as Topic; Duodenal Ulcer; Esophagitis, Peptic; Famotidine; Histamine H2 Ant | 1988 |
91 trials available for famotidine and Curling Ulcer
| Article | Year |
|---|---|
Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Histamine H2 Antag | 2020 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2012 |
[Acid-base blood balance in patients with ulcer under treatment by the gastric secretion inhibitors and antacids].
Topics: Acid-Base Equilibrium; Adolescent; Adult; Aluminum Compounds; Antacids; Duodenal Ulcer; Famotidine; | 2002 |
[Efficacy of different schemes of anti-helicobacter therapy in duodenal ulcer].
Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug | 2004 |
[Study on the efficacy of famotidine (Quamatel) in the complex treatment of erosive gastroduodenitis, stress stomach ulcer and peptic duodenal ulcer].
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Bulgaria; Duodenal Ulcer; Famotidine; Female; Gas | 2004 |
Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP | 2005 |
[Comparative study on Jinghua Weikang Capsule and famotidine in treating duodenal ulcer].
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Drug Therapy, Combination; Drugs, Chinese Herbal; Duoden | 2006 |
Colloid bismuth versus famotidine in the treatment and prevention of duodenal ulcer relapse: results of a double-blind, double dummy randomized study.
Topics: Antacids; Anti-Ulcer Agents; Bismuth; Colloids; Double-Blind Method; Duodenal Ulcer; Endoscopy, Gast | 1995 |
Maintenance of gastric pH above 6 with intravenous famotidine in patients with a bleeding duodenal ulcer.
Topics: Adult; Aged; Duodenal Ulcer; Famotidine; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; I | 1995 |
[Comparison between ranitidine, famotidine, and omeprazole in the treatment of bleeding duodenal ulcer].
Topics: Duodenal Ulcer; Famotidine; Humans; Omeprazole; Peptic Ulcer Hemorrhage; Ranitidine | 1995 |
Eradication of Helicobacter pylori by a combination of amoxicillin and famotidine.
Topics: Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Female; Gastritis; Helicobacter | 1995 |
Antibiotic versus maintenance therapy in the prevention of duodenal ulcer recurrence. Results of a multicentric double-blind randomized trial.
Topics: Adult; Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Fema | 1995 |
Prospective, randomized study of H2-blocker and triple therapy for duodenal ulcer treatment and the eradication of Helicobacter pylori.
Topics: Adult; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Female; Helicoba | 1994 |
Risk factors for delayed healing of duodenal ulcers treated with famotidine and ranitidine.
Topics: Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Humans; Male; Middle Aged; Prospective Stud | 1994 |
Prolonged bedtime treatment with H2-receptor antagonists (ranitidine and famotidine) does not affect blood alcohol levels after ethanol ingestion in male patients with duodenal ulcer.
Topics: Adult; Alcohol Dehydrogenase; Duodenal Ulcer; Ethanol; Famotidine; Helicobacter Infections; Helicoba | 1994 |
Omeprazole versus famotidine in the healing and relapse of duodenal ulcer.
Topics: Absenteeism; Adult; Analgesics; Antacids; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; H | 1993 |
[Clinical evaluation of one-year controlled studies of duodenal ulcer recurrence rate in patients treated with the preparation Ulfamid].
Topics: Adult; Duodenal Ulcer; Famotidine; Female; Follow-Up Studies; Humans; Male; Recurrence | 1993 |
Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthriti | 1996 |
Helicobacter pylori eradication with short-term therapy leads to duodenal ulcer healing without the need for continued acid suppression therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 1996 |
Candida overgrowth after treatment of duodenal ulcer. A comparison of cimetidine, famotidine, and omeprazole.
Topics: Adult; Anti-Ulcer Agents; Candidiasis; Cimetidine; Duodenal Diseases; Duodenal Ulcer; Famotidine; Fe | 1996 |
[The effect of cimetidine and famotidine on esophageal motility].
Topics: Adult; Cimetidine; Duodenal Ulcer; Esophagus; Famotidine; Female; Gastroesophageal Reflux; Histamine | 1996 |
[A multicenter clinical trial. Zinc acexamate versus famotidine in the treatment of acute duodenal ulcer. Study Group of Zinc acexamate (new UP doses)].
Topics: Acute Disease; Adult; Aged; Aminocaproates; Aminocaproic Acid; Anti-Ulcer Agents; Double-Blind Metho | 1996 |
Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Duodenal Ulcer; Famotidine; | 1997 |
Eradication of Helicobacter pylori by a 1-week course of famotidine, amoxicillin and clarithromycin.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Duodenal Ulcer; Famotidi | 1998 |
A new quadruple therapy for Helicobacter pylori using tripotassium dicitrato bismuthate, furazolidone, josamycin and famotidine.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Drug Therapy, C | 2000 |
[Comparative antisecretory activity of famotidine, omeprazole, and rabeprazole (pariet) in ulcer disease based on daily pH-monitoring].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; F | 2001 |
[Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adolescent; Adult; Aged; Anti-Ul | 1992 |
Duration of acid suppression in H2-antagonist nonresponders.
Topics: Drug Tolerance; Duodenal Ulcer; Famotidine; Female; Gastric Acid; Gastric Acidity Determination; His | 1992 |
Omeprazole versus famotidine in the short-term treatment of duodenal ulcer disease.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Metho | 1992 |
Comparative study of omeprazole and famotidine in the treatment of duodenal ulcer.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Humans; Male; Midd | 1992 |
[Therapy of peptic ulcers with famotidine. Report of experiences with an open clinical study].
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Dose-Response Relationship, Drug; Drug Administrati | 1992 |
[Time of famotidine administration and healing of duodenal ulcer: is 18.00 o'clock of importance?].
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Duodenal Ulcer; | 1992 |
Morning versus evening dose: a comparison of three H2-receptor blockers in duodenal ulcer healing.
Topics: Adult; Cimetidine; Drug Administration Schedule; Duodenal Ulcer; Famotidine; Humans; Male; Middle Ag | 1992 |
Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duoden | 1992 |
A comparative study of once-a-day morning and once-a-day bedtime administration of 40 mg famotidine in treating duodenal ulcers.
Topics: Adult; Drug Administration Schedule; Duodenal Ulcer; Famotidine; Female; Gastric Acidity Determinati | 1992 |
Prolonged gastric pH monitoring in responder and nonresponder duodenal ulcer patients: response to placebo and to H2-blocker administration.
Topics: Adult; Circadian Rhythm; Drug Resistance; Duodenal Ulcer; Famotidine; Female; Gastric Acidity Determ | 1991 |
Rebound hypersecretion after H2-antagonist withdrawal--a comparative study with nizatidine, ranitidine and famotidine.
Topics: Adult; Aged; Duodenal Ulcer; Famotidine; Gastric Acid; Gastric Acidity Determination; Gastric Mucosa | 1991 |
Famotidine vs ranitidine h.s. in acute duodenal ulcer. A multicentre endoscopic trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Double-Blind Method; Duodenal Ulcer; Endoscopy, Gastrointest | 1991 |
Day-night and individual differences in response to constant-rate ranitidine infusion.
Topics: Adult; Analysis of Variance; Circadian Rhythm; Duodenal Ulcer; Famotidine; Gastric Acid; Humans; Inf | 1991 |
A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse.
Topics: Adult; Aged; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Humans; Male; Middle Aged; Ran | 1991 |
Treatment of acute duodenal ulcers with famotidine and its comparison with other H2 blockers.
Topics: Acute Disease; Adolescent; Adult; Aged; Duodenal Ulcer; Famotidine; Female; Histamine H2 Antagonists | 1990 |
Continuous intragastric pH monitoring: a real progress in the assessment of antisecretory drugs.
Topics: Adult; Double-Blind Method; Duodenal Ulcer; Equipment Design; Famotidine; Female; Gastric Acid; Gast | 1990 |
Dopamine agonists prevent duodenal ulcer relapse. A comparative study with famotidine and cimetidine.
Topics: Adult; Aged; Amantadine; Bromocriptine; Cimetidine; Duodenal Ulcer; Famotidine; Female; Humans; Male | 1991 |
Double-blind comparison of the safety and efficacy of famotidine with ranitidine in patients with endoscopically diagnosed peptic ulcer.
Topics: Adult; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Humans; India; Male; Ranitidine; Sto | 1990 |
[Famotidine in the treatment of duodenal peptic ulcer].
Topics: Adult; Duodenal Ulcer; Famotidine; Female; Humans; Male; Middle Aged; Peru | 1990 |
A multicentre, randomized, double-blind study comparing nocte famotidine or ranitidine for the treatment of active duodenal ulceration.
Topics: Adult; Aged; Antacids; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Humans; Male; Middle | 1989 |
A single night-time dose of famotidine is equivalent to ranitidine in decreasing 24-hour gastric acidity in asymptomatic duodenal ulcer subjects.
Topics: Adult; Double-Blind Method; Duodenal Ulcer; Famotidine; Gastric Acid; Gastric Acidity Determination; | 1989 |
Single night-time doses of 40 mg famotidine or 800 mg cimetidine in the treatment of duodenal ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aluminum Hydroxide; Antacids; Cimetidine; Double-Blind M | 1989 |
Comparison between single morning and bedtime doses of 40 mg famotidine for the treatment of duodenal ulcer.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Drug Administration Schedule; Duodenal Ulcer; Famotidi | 1989 |
Famotidine in the treatment of duodenal ulcers resistant to other histamine H2-receptor antagonists.
Topics: Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Female; Histamine H2 Antagonists; Humans | 1989 |
Famotidine therapy for active duodenal ulcers. A multivariate analysis of factors affecting early healing.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Duodenal | 1989 |
Comparison of the effects of placebo, ranitidine, famotidine and nizatidine on intragastric acidity by means of continuous pH recording.
Topics: Adult; Circadian Rhythm; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Gastric Acid; Gast | 1989 |
A multicenter, randomized, double-blind study comparing famotidine with cimetidine in the treatment of active duodenal ulcer disease.
Topics: Adult; Cimetidine; Double-Blind Method; Drug Administration Schedule; Duodenal Ulcer; Famotidine; Fe | 1989 |
A multicenter, randomized, double-blind study comparing once-daily bedtime administration of famotidine and ranitidine in the short-term treatment of active duodenal ulcer.
Topics: Adult; Anti-Ulcer Agents; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedul | 1989 |
A multicenter, randomized, double-blind study comparing a daily bedtime administration of famotidine and ranitidine in short-term treatment of active duodenal ulcer.
Topics: Adult; Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Duodenal Ulcer; Famotid | 1989 |
[Comparative efficacy of famotidine and ranitidine in the treatment of acute-phase duodenal ulcer. A French comparative therapeutic trial].
Topics: Acute Disease; Adolescent; Adult; Aged; Cicatrix; Clinical Trials as Topic; Double-Blind Method; Dru | 1989 |
[Famotidine versus ranitidine in the acute treatment of duodenal ulcer. A multicenter comparative study in Germany].
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Me | 1985 |
Famotidine in the management of duodenal ulcer: experience in Italy.
Topics: Adult; Circadian Rhythm; Clinical Trials as Topic; Double-Blind Method; Duodenal Ulcer; Famotidine; | 1985 |
Famotidine versus ranitidine for the short-term treatment of duodenal ulcer.
Topics: Adolescent; Adult; Aged; Antacids; Clinical Trials as Topic; Dose-Response Relationship, Drug; Doubl | 1985 |
Famotidine in the treatment of gastric and duodenal ulceration: overview of clinical experience.
Topics: Acute Disease; Chronic Disease; Cimetidine; Circadian Rhythm; Clinical Trials as Topic; Double-Blind | 1985 |
[Famotidine versus placebo in prevention of the recurrence of duodenal ulcer disease. A multicenter study in Germany, Austria and Italy].
Topics: Adult; Austria; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Duodena | 1985 |
Treatment of active duodenal ulcers with famotidine. A double-blind comparison with ranitidine.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Hist | 1986 |
A multicenter, randomized, double-blind study comparing famotidine with ranitidine in the treatment of active duodenal ulcer disease.
Topics: Adolescent; Adult; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Duod | 1986 |
Maintenance therapy of duodenal ulcer with famotidine. A multicenter United States study.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Duodenal U | 1986 |
A multicenter, double-blind, randomized, placebo-controlled comparison of nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer disease.
Topics: Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Duodenal Ulcer; Famotid | 1987 |
Famotidine (Pepcid).
Topics: Clinical Trials as Topic; Duodenal Ulcer; Famotidine; Gastric Acid; Histamine H2 Antagonists; Humans | 1987 |
[Comparison of famotidine and ranitidine in duodenal ulcer].
Topics: Clinical Trials as Topic; Duodenal Ulcer; Famotidine; Histamine H2 Antagonists; Humans; Ranitidine; | 1987 |
Comparison of famotidine 40 mg with ranitidine 300 mg at night in short-term duodenal ulcer healing. A South African multicentre study.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Histamine | 1987 |
Review of an extensive worldwide study of a new H2-receptor antagonist, famotidine, as compared to ranitidine in the treatment of acute duodenal ulcer.
Topics: Acute Disease; Adult; Antacids; Duodenal Ulcer; Famotidine; Female; Histamine H2 Antagonists; Humans | 1987 |
Comparison of once-daily bedtime administration of famotidine and ranitidine in the short-term treatment of duodenal ulcer. A multicenter, double-blind, controlled study.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule | 1987 |
Effect of oral famotidine on 24-hour intragastric acidity.
Topics: Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Drug Evaluation; Duodenal Ulcer | 1986 |
H2-receptor antagonists and duodenal ulcer recurrence: analysis of efficacy and commentary on safety, costs, and patient selection.
Topics: Cimetidine; Clinical Trials as Topic; Costs and Cost Analysis; Duodenal Ulcer; Famotidine; Histamine | 1987 |
Action of famotidine and ranitidine on prostaglandin E2 (PGE2) content of fundic and duodenal mucosa in duodenal ulcer patients.
Topics: Adult; Dinoprostone; Duodenal Ulcer; Famotidine; Female; Gastric Mucosa; Histamine H2 Antagonists; H | 1987 |
Single bedtime dose of famotidine: assessment of its antisecretory action by 24-hour intragastric pH monitoring.
Topics: Adult; Drug Administration Schedule; Duodenal Ulcer; Famotidine; Female; Gastric Acid; Gastric Acidi | 1987 |
Once and twice daily doses of H2 antagonists revisited, using continuous intragastric pH monitoring.
Topics: Adult; Clinical Trials as Topic; Duodenal Ulcer; Famotidine; Female; Gastric Acid; Gastric Acidity D | 1988 |
Overnight comparable anacidity by standard large and half-single bedtime doses of H2 antagonists in duodenal ulcer patients: a clinical pharmacological study.
Topics: Adult; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; Duodenal Ulcer; Fam | 1988 |
Histamine H2-receptor antagonists.
Topics: Animals; Clinical Trials as Topic; Duodenal Ulcer; Esophagitis, Peptic; Famotidine; Histamine H2 Ant | 1988 |
Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients?
Topics: Adult; Circadian Rhythm; Drug Interactions; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; G | 1988 |
[Acute treatment of duodenal ulcer. Results of an open multicenter study with famotidine nocte].
Topics: Anti-Ulcer Agents; Clinical Trials as Topic; Drug Administration Schedule; Duodenal Ulcer; Famotidin | 1988 |
Famotidine versus cimetidine in the treatment of acute duodenal ulcer. Double-blind, randomized clinical trial comparing nocturnal administration of 40 mg famotidine to 800 mg cimetidine.
Topics: Acute Disease; Adult; Aged; Anti-Ulcer Agents; Cimetidine; Clinical Trials as Topic; Double-Blind Me | 1988 |
Famotidine in the short and long-term treatment of duodenal ulcer.
Topics: Anti-Ulcer Agents; Clinical Trials as Topic; Double-Blind Method; Duodenal Ulcer; Famotidine; Female | 1988 |
Famotidine in the management of duodenal ulcer: an analysis of multicenter findings worldwide.
Topics: Drug Administration Schedule; Duodenal Ulcer; Evaluation Studies as Topic; Famotidine; Humans; Meta- | 1988 |
A comparison of the effects on intragastric acidity of bedtime or dinnertime administration of a once daily dose of famotidine.
Topics: Adult; Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Duodenal Ulcer; Famotid | 1988 |
Continuous intravenous infusions of famotidine maintain high intragastric pH in duodenal ulcer.
Topics: Adult; Aged; Anti-Ulcer Agents; Clinical Trials as Topic; Double-Blind Method; Duodenal Ulcer; Famot | 1988 |
Continuous 24-hour intragastric pH monitoring in the evaluation of the effect of a nightly dose of famotidine, ranitidine and placebo on gastric acidity of patients with duodenal ulcer.
Topics: Adult; Anti-Ulcer Agents; Clinical Trials as Topic; Duodenal Ulcer; Famotidine; Female; Gastric Acid | 1987 |
Famotidine in the short-term treatment of duodenal ulcer and of concomitant peptic lesions: comparison with cimetidine.
Topics: Cimetidine; Duodenal Ulcer; Famotidine; Female; Humans; Male; Middle Aged; Peptic Ulcer; Thiazoles | 1988 |
Summary of the 30th meeting of the Food and Drug Administration Gastrointestinal Drugs Advisory Committee January 16-17, 1986.
Topics: Aluminum; Cimetidine; Clinical Trials as Topic; Duodenal Ulcer; Famotidine; Humans; Peptic Ulcer; Su | 1986 |
Effects of 800 mg cimetidine once daily on gastric acid secretion.
Topics: Administration, Oral; Cimetidine; Circadian Rhythm; Clinical Trials as Topic; Duodenal Ulcer; Famoti | 1986 |
[Acute therapy of duodenal ulcer. Comparison of famotidine and ranitidine in a single evening dose].
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Ulcer Agents; Clinical Trials as Topic; Double-Blind Me | 1987 |
Famotidine once-a-day in the management of duodenal ulcer: the U.S. placebo-controlled experience.
Topics: Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Duodenal Ulcer; Famotidine; Hu | 1987 |
67 other studies available for famotidine and Curling Ulcer
| Article | Year |
|---|---|
[Prophylaxis of an acute postoperative pancreatitis and the stress ulcers occurrence after operations, performed on organs of hepatopancreatoduodenal zone, using miniinvasive and open access].
Topics: Acute Disease; Drug Administration Schedule; Drug Dosage Calculations; Duodenal Ulcer; Endoscopy, Ga | 2014 |
A fixed-dose combination ibuprofen and famotidine (Duexis).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Combinations; Duodenal Ulcer; F | 2011 |
Editorial: single-tablet ibuprofen/double-dose famotidine for reduction of gastric and duodenal ulcers (REDUCE Trials): what can be reduced?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Female; Huma | 2012 |
[Pharmacotherapy of non-associated with Helicobacter pylori ulcer].
Topics: Adult; Antacids; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Female; Helicobacter pylori; Humans; | 2002 |
Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level.
Topics: Adult; Anti-Ulcer Agents; Area Under Curve; Cimetidine; Duodenal Ulcer; Famotidine; Female; Gastrins | 2002 |
Effect of exogenous administration of transforming growth factor-beta and famotidine on the healing of duodenal ulcer under the impact of indomethacin.
Topics: Animals; Duodenal Ulcer; Famotidine; Gastric Acid; Indomethacin; Male; Rats; Rats, Wistar; Transform | 2003 |
[Clinical and economic analysis of the application of ranitidine and famotidine for treatment of duodenal ulcers].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Drug Costs; Duodenal Ulcer; Famotidin | 2005 |
[Complex evaluation of the action of inhibitors of hydrochloric acid secretion on gastric function in ulcer disease].
Topics: Adult; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Famotidine; | 2006 |
Effects of antiulcer agents on healing of mepirizole-induced duodenal ulcers in rats.
Topics: Aluminum Hydroxide; Animals; Anti-Ulcer Agents; Cimetidine; Drug Combinations; Duodenal Ulcer; Epiri | 1983 |
[Effect of Famotidine in gastric acidity, plasma secretin and gastrin in duodenal ulcer patients. With reference to 24-hour intragastric pH monitoring].
Topics: Adult; Duodenal Ulcer; Famotidine; Female; Gastric Acid; Gastric Acidity Determination; Gastric Muco | 1984 |
[Effects of protective agents on ulcer formation].
Topics: Adult; Animals; Cimetidine; Dogs; Duodenal Ulcer; Famotidine; Gastric Juice; Gastric Mucosa; Humans; | 1984 |
Peptic ulcer disease in adolescence: changing concepts in the age of Helicobacter pylori.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Helicobacter Infections; Helicobac | 1994 |
[Maintenance therapy with antiulcer drugs: review of 71 cases].
Topics: Aluminum Hydroxide; Antacids; Anti-Ulcer Agents; Carbonates; Cross-Over Studies; Duodenal Ulcer; Fam | 1995 |
Blood alcohol levels after prolonged histamine-2-receptor antagonist treatment.
Topics: Duodenal Ulcer; Ethanol; Famotidine; Histamine H2 Antagonists; Humans; Male; Random Allocation; Rani | 1994 |
YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.
Topics: Animals; Anti-Ulcer Agents; Benzodiazepines; Duodenal Ulcer; Epirizole; Ethanol; Famotidine; Gastric | 1994 |
Inhibition of phase III activity by acid in canine stomach.
Topics: Animals; Disease Models, Animal; Dogs; Duodenal Ulcer; Electrodes; Electrophysiology; Famotidine; Fe | 1994 |
Maintenance of intragastric pH > 4 with famotidine in duodenal ulcer patients: factors influencing drug requirements.
Topics: Adult; Aged; Drug Delivery Systems; Duodenal Ulcer; Duodenum; Famotidine; Female; Fibrosis; Gastric | 1994 |
Healing-promoting action of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy]propyl]urea with dual action on chronic gastric and duodenal ulcers induced by acetic acid in rats.
Topics: Acetates; Animals; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Duodenal Ulcer; Famotidine; | 1993 |
Hepatitis following treatments with famotidine and then cimetidine.
Topics: Chemical and Drug Induced Liver Injury; Cimetidine; Duodenal Ulcer; Famotidine; Fatty Liver; Female; | 1994 |
Long term acid suppressing treatment in general practice.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; | 1994 |
[Evaluation of microsomal enzyme function in the liver in patients with duodenal ulcer treated with famotidine].
Topics: Adult; Duodenal Ulcer; Famotidine; Female; Humans; Male; Microsomes, Liver; Middle Aged | 1993 |
[Assessment of microsomal enzyme function in liver of patients with duodenal ulcer treated with famotidine].
Topics: Adult; Aminopyrine; Breath Tests; Duodenal Ulcer; Famotidine; Female; Humans; Male; Microsomes, Live | 1993 |
Gastric acid inhibits antral phase III activity in duodenal ulcer patients.
Topics: Adult; Duodenal Ulcer; Duodenum; Famotidine; Female; Gastric Acid; Gastric Acidity Determination; Ga | 1993 |
The effect of the combination therapy with sucralfate and famotidine on experimentally induced duodenal ulcers in rats.
Topics: Animals; Anti-Ulcer Agents; Cysteamine; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Femal | 1996 |
New drug to prevent NSAID-related ulcers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulce | 1996 |
[Ulfamid in the combined therapy of gastric and duodenal peptic ulcer].
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Combined Modality Therapy; Drug Evaluation; Drug Therap | 1997 |
[Conservative treatment of ulcer hemorrhage with histamine H2 antagonists].
Topics: Adolescent; Adult; Duodenal Ulcer; Endoscopy, Digestive System; Famotidine; Follow-Up Studies; Hista | 1997 |
Enhancement of neutrophil infiltration in the corpus after failure of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biop | 1997 |
Bone mineral density in patients taking H2-receptor antagonist.
Topics: Adult; Aged; Bone Density; Case-Control Studies; Cimetidine; Duodenal Ulcer; Famotidine; Female; His | 1998 |
[Bicarbonate deficiency and duodenal peptic ulcer].
Topics: Acid-Base Equilibrium; Adult; Bicarbonates; Chronic Disease; Duodenal Ulcer; Famotidine; Female; Gas | 1998 |
Effect of chronic acid inhibition on duodenal bulb gastric metaplasia and Helicobacter pylori.
Topics: Adult; Case-Control Studies; Duodenal Ulcer; Duodenum; Famotidine; Female; Gastric Mucosa; Helicobac | 1998 |
[Antisecretory effects of quamatel and gastrocepin in duodenal ulcer: comparison with intragastric pH-metry].
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Female; Follow-Up Studies; G | 1998 |
[Famotidine (quamatel) for treatment of ulcer disease].
Topics: Adolescent; Adult; Duodenal Ulcer; Endoscopy, Digestive System; Famotidine; Follow-Up Studies; Hista | 1999 |
Simple closure of perforated duodenal ulcer.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Female; Humans; Male; Middle | 1998 |
The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Chile; Developing Countries; Drug Therapy, | 2000 |
[24-hour monitoring of gastric juice pH in assessment of anti-ulcer treatment].
Topics: Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Biopsy; Circadian Rhythm; Drug Therapy | 2000 |
[Famotidin (quamatel) in the treatment of gastroduodenal ulcer].
Topics: Adult; Drug Administration Routes; Duodenal Ulcer; Endoscopy, Digestive System; Famotidine; Female; | 2000 |
[Quamatel application in three-drug eradication therapy of duodenal ulcer and gastroduodenal ulcerations associated with helicobacter pylori infection].
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Duodenal Ulcer; Fa | 2000 |
[Experience in clinical use of quamatel in upper gastrointestinal hemorrhage].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Duodenal Ulcer; Famotidine; Female; Gastroin | 2001 |
[H2 blockers in the treatment of bleeding gastroduodenal ulcers].
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Duodenoscopy; Famotidine; Female; Gastro | 2001 |
[Effect of exogenous administration of platelet-derived growth factor and epidermal growth factor on duodenal ulcer healing in rats treated with indomethacin].
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Ep | 2002 |
[The gastric mucigenous function in the treatment of patients with ulcer with various antisecretory preparations].
Topics: Adult; Anti-Ulcer Agents; Duodenal Ulcer; Enzyme Inhibitors; Famotidine; Female; Gastric Acidity Det | 2002 |
Primary hyperparathyroidism with duodenal ulcer and H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenoma; Aged; Anti-Ulcer Agents; Benzimidazoles; Duodenal | 2002 |
[Prevention of the recurrence of duodenal ulcer with famotidine. Report of experiences with long-term therapy in an open clinical study].
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Duodenal Ulcer; Duodenoscopy; | 1992 |
Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Duodenal Ulcer; Duodenum; Esoph | 1991 |
Definition for idiopathic gastric acid hypersecretion. A statistical and functional evaluation.
Topics: Adult; Cimetidine; Duodenal Ulcer; Famotidine; Female; Gastric Acid; Humans; Male; Middle Aged; Rani | 1991 |
The histological maturity of regenerating mucosa of healed duodenal ulcer and ulcer recurrence after treatment with H2-antagonist.
Topics: Adolescent; Adult; Aged; Cimetidine; Duodenal Ulcer; Duodenoscopy; Famotidine; Female; Histamine H2 | 1990 |
Effects of FRG-8701 on gastric acid secretion, gastric mucosal lesions by necrotizing agents and experimental gastric or duodenal ulcer in rats.
Topics: Acetamides; Animals; Cimetidine; Duodenal Ulcer; Famotidine; Gastric Acid; Gastric Mucosa; Guinea Pi | 1990 |
High doses of ranitidine in maintenance therapy of duodenal ulcer patients.
Topics: Cimetidine; Duodenal Ulcer; Famotidine; Humans; Ranitidine; Recurrence; Smoking | 1990 |
Effect of an endogenous satiety substance, 2-buten-4-olide, on gastric acid secretion and experimental ulceration in rats.
Topics: 4-Butyrolactone; Animals; Cimetidine; Cysteamine; Deoxyglucose; Duodenal Ulcer; Famotidine; Furans; | 1990 |
A single nocte dose of famotidine in the treatment of duodenal ulcer.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Female; Histamine H2 Antagon | 1989 |
[Famotidine in the short and long term treatment of duodenal ulcer: clinical and physiopathologic study].
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Drug Administration Schedule; Drug Evaluation; Duodenal | 1989 |
Failure of single night-time dose of H2-receptor antagonists in the treatment of duodenal ulcer patients with bulbar stenosis.
Topics: Adult; Aged; Drug Administration Schedule; Duodenal Obstruction; Duodenal Ulcer; Famotidine; Female; | 1989 |
Low doses of H2 antagonists and interaction with anticholinergics.
Topics: Drug Synergism; Duodenal Ulcer; Famotidine; Gastric Acidity Determination; Humans; Pirenzepine; Rani | 1989 |
[Duodenal ulcer, study of gastric secretion and rational treatment with famotidine in different doses].
Topics: Duodenal Ulcer; Famotidine; Gastric Acid; Humans | 1989 |
Clinical pharmacology of famotidine.
Topics: Animals; Cimetidine; Circadian Rhythm; Dogs; Dose-Response Relationship, Drug; Duodenal Ulcer; Famot | 1985 |
[Famotidine. Pharmacologic and clinical profile of the new histamine H2 receptor antagonist].
Topics: Animals; Duodenal Ulcer; Famotidine; Guinea Pigs; Histamine H2 Antagonists; Humans; Kinetics; Stomac | 1986 |
Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
Topics: Duodenal Ulcer; Famotidine; Gastric Acid; Histamine H2 Antagonists; Humans; Recurrence; Stomach Ulce | 1987 |
Antisecretory and antiulcer effect of the H2-receptor antagonist famotidine in the rat: comparison with ranitidine.
Topics: Animals; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Female; Gastric Emptying; Gastric Mucosa; Hi | 1987 |
Effect of mifentidine on mepirizole-induced duodenal ulcer in the rat.
Topics: Animals; Anti-Ulcer Agents; Cimetidine; Dose-Response Relationship, Drug; Duodenal Ulcer; Duodenum; | 1987 |
[Famotidine treatment of patients with gastric and duodenal ulcers. A comparative study with once or twice-a-day administration].
Topics: Adult; Aged; Anti-Ulcer Agents; Drug Evaluation; Duodenal Ulcer; Famotidine; Histamine H2 Antagonist | 1987 |
The cost-effectiveness of maintenance therapy for duodenal ulceration with an H2-antagonist.
Topics: Cost-Benefit Analysis; Duodenal Ulcer; Famotidine; Histamine H2 Antagonists; Humans | 1988 |
Refractory duodenal ulcers (nonhealing duodenal ulcers with standard doses of antisecretory medication).
Topics: Adult; Aged; Anti-Ulcer Agents; Cimetidine; Duodenal Ulcer; Famotidine; Female; Gastric Acid; Humans | 1989 |
[Famotidine in the therapy and prevention of duodenal ulcer].
Topics: Adult; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Female; Humans; Male; Ranitidine; Thiazoles | 1988 |
Famotidine has no significant effect on gonadal function in man.
Topics: Administration, Oral; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Follicle Stimulating Hor | 1988 |
Healing and relapse rates of duodenal ulcer with various H2 receptor antagonists.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Cimetidine; Duodenal Ulcer; Famotidine; Female; Humans; Male; | 1988 |
Comparison of the effects of gastric antisecretory agents in healthy volunteers and patients with duodenal ulcer.
Topics: Anti-Ulcer Agents; Cimetidine; Drug Administration Schedule; Duodenal Ulcer; Famotidine; Gastric Aci | 1986 |